University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Summer 8-19-2016

The Role of Glutaminase and Extracellular Vesicles in
Macrophages and Microglia
Beiqing Wu
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Infectious Disease Commons, Nervous System Commons, Nervous System Diseases
Commons, and the Neurology Commons

Recommended Citation
Wu, Beiqing, "The Role of Glutaminase and Extracellular Vesicles in Macrophages and Microglia" (2016).
Theses & Dissertations. 121.
https://digitalcommons.unmc.edu/etd/121

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

The Role of Glutaminase and Extracellular Vesicles in Macrophages and
Microglia

By

Beiqing ‘Mercury’ Wu

A DISSERTATION
Presented to the Faculty of
The Graduate College in the University of Nebraska
In Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy

Department of
Pharmacology and Experimental Neuroscience

Under the Supervision of Dr. Jialin Zheng
Medical Center
Omaha, Nebraska
June, 2016

The Role of Glutaminase and Extracellular Vesicles in Macrophages and
Microglia

Beiqing ‘Mercury’ Wu, M.D. Ph.D.
University of Nebraska, 2016
Advisor: Jialin Zheng, M.D.
Glutamate serves as a crucial excitatory neurotransmitter that is essential
for the proper functioning of the brain. However, excess levels of glutamate are
neurotoxic and contribute to the pathogenesis of various neurodegenerative
diseases,

inducing

HIV-1

associated

neurocognitive

disorders

(HAND).

Glutaminase 1 (GLS1) is an important mitochondrial enzyme responsible for
producing glutamate from glutamine. GLS1 is upregulated during HAND and
released from mitochondria to cytosol and extracellular space. However, why and
how GLS1 is released remains unknown. In chapter II, we demonstrated that
extracellular vesicles (EVs) carry GLS1 as cargos from cytosol to extracellular
space during HIV infection and innate immune activation. The GLS-containing
EVs induce neurotoxicity through the overproduction of glutamate, implicating the
pathogenic role of EVs and GLS1 in HAND.
Regulation of EV remains to be fully elucidated in HAND. Interestingly,
when carried as cargo, GLS1 showed a potential effect on the release of EV.
Therefore, we hypothesize that the release of EV is dependent on GLS1mediated glutamine and sphingolipid metabolism. In chapter III, we investigated
the involvement of GLS1 in EV release in GLS1-overexpressing HeLa cells, HIV-

1-infected macrophages, and immune-activated microglia through the use of
GLS1 inhibitors. In the aforementioned cell types, GLS1 inhibitor significantly
decreased the level of EVs, suggesting an important role of GLS1 in EV
regulation. In chapter IV, we further investigated the mechanism of GLS1mediated EV release. We identified that GLS1-mediated EV release is
dependent upon the level of glutamine and a-ketoglutarate (a-KG). Because
a-KG is an important metabolite of glutamate, these data suggest that a-KG is an
essential GLS1 downstream factor that regulates the release of EVs. Biogenesis
of EVs requires the sphingolipid ceramide. However, it is unknown whether
GLS1-mediated EV release involves ceramide. We have demonstrated that the
addition of ceramide rescued the suppression of EV release by GLS1 inhibitors,
suggesting that GLS1 mediates EV release through ceramide.
In summary, our data revealed two interesting insights into the biology of
EVs. First, GLS-containing EVs is a pathogenic component of neurodegeneration
in HAND. Second, the release of EVs is dependent on GLS1-mediated glutamine
and sphingolipid metabolism. Studies on both of these aspects in EVs could lead
to potential novel therapeutic targets for HAND and other neurodegenerative
diseases.
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1.1 HIV-1 associated neurocognitive disorders
1.1.1 Clinical manifestation
As reported by UNAIDS in 2014 (UNAIDS), approximately 35 million
people worldwide are infected with Human Immunodeficiency Virus (HIV), which
continues to cause significant morbidities [1]. Among the cases of HIV infection,
more than 90% of the global HIV pandemic attributes to HIV-1 infection but not
HIV-2 [2].
In addition to immune compromise, HIV infection causes a wide spectrum
of HIV-1-associated neurocognitive disorders (HAND), which range from mild
cognitive disease to dementia, even under the treatment of successful antiretroviral therapy [3, 4]. HAND is characterized by cognitive deteriorations,
behavioral impairments and motor function loss due to progressive neuronal
damage. HAND consists of three major classifications based on guidelines in the
measurements of cognitive dysfunction: HIV-1 associated dementia (HAD), mild
neurocognitive disorder (MND), and asymptomatic neurocognitive impairment
(ANI) [4-6]. Thanks to the effective treatment of highly active antiretroviral therapy
(HAART), the prevalence of the most severe form of HAND, HAD has been
dramatically reduced [7]. However, the incidence of the moderate and mild forms
of HAND remains high and cannot be ignored [7-9]. Recent reports have shown
that the increasing resistance to the antiretroviral drug can be caused to the
following reasons: the increasing viral mutation, the increasing lifespan of HIVinfected individuals, and the compromised blood-brain barrier (BBB) disturbed by
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HAART [10-12]. Mononuclear phagocytes, including macrophages and microglia,
are found to be HIV reservoirs [7, 13, 14].
The quality of life for HIV individuals is significantly affected because of
the difficulty in obtaining employment due to discrimination/disease burden and a
decreased ability to perform complex daily tasks due to HAND. Examples of
impairments include finance management and housekeeping, and poor quality of
life and poor compliance to medical instructions [4, 15-18]. Despite peripheral
control of HIV replication by HAART, 60% - 90% of the individuals have a certain
degree of cognitive disease [1, 19].

1.1.2 Pathobiology of HAND
HIV-1 associated dementia is the most severe form of HAND, which is a
chronic disease state in progressive HIV-1 infection with HIV encephalopathy or
AIDS dementia complex [7, 20]. During HIV-1 infection, HIV virus infects
circulating monocyte/macrophages and enters the central nervous system (CNS)
within weeks after the initial infection through a ‘Trojan horse’ mechanism, which
impairs the cognition including attention, memory, language, problem solving and
decision making [1, 20]. The other symptoms of HAND include confusion,
forgetfulness, behavioral changes, headaches, gradual weakening and loss of
falling in the arms and legs, problems with cognition or movement and pain due
to nerve damage (NIH) [21-23].
HAND correlates with HIV-1 encephalitis (HIVE) histologically [24].
Studies with in situ hybridization indicate that productive HIV-1 infections appear
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exclusively in perivascular monocyte-derived macrophages (MDM) [25-27]. The
post-mortem pathology reports from HAD patient brain sections show
progressive infection and infiltration of perivascular MDM, which results in the
formation of multinucleated giant cells [26, 27]. Activated perivascular
macrophages activate astrocytes and lead to reactive astrogliosis, myelin pallor
and white mater diffusion, reduction in synaptic density, increased BBB
permeability, and neuronal damage or loss [21, 28].
In the pre-HAART era, approximately 40% reduction in neuronal densities
in the frontotemporal cortex [21, 29], and 50%-90% reduction in neuronal
densities in the hippocampus were reported [30]. Highly regulated cell death,
known as apoptosis, was believed to be the major cause of neuronal loss.
Recent observations of samples from HAND patients with treatment of HAART
still showed decrease of neuronal loss and further neuronal damage [31-33]. The
neuronal damage in the areas of the brain such as basal ganglia, cerebral cortex,
and hippocampus in HAND patients’ causes significant cognitive impairment [34].
HIV majorly infects brain microglia and macrophages. Infection of
astrocytes is restricted because of the lack of CD4 presence on the cells [35-38].
Although neurons are not susceptible to HIV, neurons are largely affected by the
HIV-infected neighboring cells in the CNS [39, 40], such as HIV-infected
astrocytes, macrophages and microglia, due to the production of viral proteins,
cytokines and neurotoxins [41-46]. The elevation of these neurotoxic factors
contributes to the damage of synapses, impairment of neuronal function and
chronic inflammation. This leads to the disruption of the connections of the
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neuronal

network

and

impaired

neurotransmission,

and

thus

causes

neurodegeneration [47-51]. Studies show that the viral proteins released by
infected macrophages and microglia further infect uninfected cells in the CNS,
and release a variety of proinflammatory molecules and neurotoxins, which
causes further neuronal damage and leads to more severe form of HAND [52,
53].

1.2 Macrophage and microglia activation
Macrophages and microglia are mature mononuclear phagocytes (MPs)
that are both crucial to the innate and adaptive immune responses. MPs engulf
pathogens and cellular debris, process them into small peptides of 10-14 amino
acids and present them onto the cell surface. Antigens can be presented to
appropriate specific T cells receptor, which leads to a high-affinity interaction
between antigen presenting cells (APC) and T N-Methyl-D-aspartic acid cells and
initiates T cell activation. MPs stimulate the immune response through the
production of inflammatory cytokines and chemokines, and further amplifying the
immune response [54, 55].
Both macrophages and microglia are believed to be pivotal in the
pathogenesis of neurodegenerative disease, particularly HAND. During HAND,
MPs infiltrated into the CNS through the BBB. There, MPs acquire enhanced
phagocytic capability, secrete proinflammatory cytokines and chemokines, and
release cytotoxic factors. All of these events lead to injury to bystander cells
including neurons [48, 56]. In the past, there was controversy over whether or not
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MPs express neurotrophic factors during brain inflammation or clear pathogens
through phagocytosis. Recent studies have shown that MPs do perform both
functions, and that these functions account for the pathogenesis of HAND.
During HAND, HIV establishes a latent and persistent infection within
MPs, which serves as a viral reservoir and allows HIV to evade immune
surveillance. HIV in the CNS primarily exists within the perivascular blood and
parenchymal brain macrophages and microglia [41]. Neurons, astrocytes,
oligodendrocytes and endothelial cells in the brain are barely infected by HIV [22,
57, 58]. MPs are the major population that produces and releases a variety of
neurotoxins into the brain [41-45, 59-62], including platelet activating factor [6365], arachidonic acid [66], pro-inflammatory cytokines and chemokines [67],
quinolinic acid [68, 69], nitric oxide [70] and excess glutamate [71, 72]. MPs have
been believed to be immune protective. However, MPs can also be responsible
for tissue damage. The mechanism wherein activated MPs during HIV infections
can induce neuronal injury remains to be elucidated.

1.3 Excitotoxicity
Chronic neuroinflammation contributes to the major pathogenesis of
neurodegenerative diseases including HAND, amyotrophic lateral sclerosis,
multiple sclerosis, Parkinson’s disease and Alzheimer’s disease [48, 49, 51].
Brain inflammation has been suggested to be closely associated with neuronal
injury [47, 73]. HIV infection and immune stimulation activate microglia and
macrophages, which induce brain inflammation and neuronal damage via
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production of a variety of soluble neurotoxic factors [70, 74] including viral
proteins, platelet activating factors, proinflammatory cytokines and chemokines,
nitric oxide, and excess glutamate [46, 50, 75-77]. In neurodegenerative
pathology, the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and
interleukin-1β (IL-1β) are released in increasing concentrations, which induces
neuronal damage via the excess release of glutamate [78].
Glutamate is one of the most important excitatory neurotransmitters and
secondary messengers in the mammalian CNS [79, 80]. Glutamate plays a
pivotal role in physiologic function regarding neural development, synaptic
plasticity, learning and memory [81, 82]. Glutamate is packaged into presynaptic
vesicles, which are recruited and docked to the release sites onto the dense
electron active zones of presynaptic neurons [83]. After glutamate-containing
vesicles are exocytosed into the synaptic cleft from the presynaptic nerve
terminals with the intracellular calcium influxes, glutamate binds to glutamate
receptors on the postsynaptic neurons [84-86]. The binding alters membrane
potential of the postsynaptic neurons and thus the downstream signal
transduction cascades.
There are three major downstream pathways of glutamate. First,
glutamate is taken up by postsynaptic neurons for neuronal signal transmission.
Second, glutamate can be taken up by presynaptic neurons through glutamate
transporters. Third, the extra amount of glutamate in the synaptic cleft will be
taken up by neighboring astrocytes through glutamate transporters at a sodiumdependent mechanism [87-89].
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Studies also show that glutamate can potentially lead to extensive
neuronal damage and excitotoxicity at excess level via the overactivation of
glutamate receptors, which are N-Methyl-D-Aspartate (NMDA) receptors on
neurons [90]. Neurotoxic viral proteins, such as HIV-1 coat protein glycoprotein
120 (Gp120) and HIV trans-acting protein Tat, can induce modification of the
kinetics of NMDA receptors located on postsynaptic neurons through the
stimulation of the release of arachidonic acid from infected glial cells [91]. The
increasing production of extracellular glutamate contributes to the overactivation
of NMDA receptors and the calcium overload within neurons [92, 93]. Calcium
has long been understood as one of the most important secondary messengers
in neural signal transduction. When dysregulated, calcium leads to oxidative
stress including increasing production of free radicals, disruption of redox
balance, mitochondrial dysfunction, caspase activation and cell death [94]. It has
been

reported

that

memantine,

a

moderate-affinity

glutamate

receptor

antagonist, can reverse HIV viral protein-induced calcium overload in neurons
and apoptosis. The inhibition of NMDA receptor, dizocilpine (MK-801), reverses
the excitotoxicity in neurons induced by glutamate, which confirms the
importance of glutamate in excitotoxicity [95, 96].
Furthermore, during HIV infection, the ability of astrocytes to absorb the
extra amounts of glutamate in the extracellular space is impaired due to the
dysfunction of the glutamate transporters, which exacerbates the excess levels of
glutamate and further induces excitotoxicity [97-101].
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In summary, elevation in extracellular glutamate levels has been proven to
be associated with the pathogenic processes of various CNS disorders and
neurodegenerative diseases including HAND [72, 102-104].

1.4 Glutaminase 1
Glutaminase is a phosphate-activated amidohydrolase, which deaminases
glutamine into glutamate in the mammalian CNS [105]. Two major types of
glutaminase have been identified in mammals, kidney-type glutaminase and
liver-type glutaminase. Kidney-type glutaminase, also known as glutaminase 1
(GLS1) is the predominant enzyme to utilize glutamine to produce glutamate.
GLS1 is a hetero-tetramer, located in the inner membrane of mitochondria. GLS1
is found abundantly expressed in a variety of cells in CNS. Liver-type
glutaminase, or glutaminase 2 (GLS2) is expressed at lower levels in the brain
[106].
GLS1 and GLS2 are encoded by separate genes on different
chromosomes. The human Gls1 gene is located on chromosome 2 and has two
major isoforms attributed to tissue-specific alternative splicing [107, 108]. In a
twist of confusing nomenclature, one of the isoforms of GLS1 is named kidneytype glutaminase (KGA), while the other isoform is known as glutaminase C
(GAC). These two splice variants of GLS1, are found abundantly in mammalian
brain tissues [109]. KGA and GAC transcribe exons 1-14 in the N-terminal and
share the same functional region of KGA from 230 to 550 AA. KGA and GAC
have a unique C-terminal, respectively, where KGA transcribes exons 16-19 and
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GAC transcribes exon 15 [109]. When glutamine is catalyzed by glutaminase into
glutamate,

glutamate

is

subsequently

further

catalyzed

by

glutamate

dehydrogenase into α-ketoglutarate. Subsequently, α-ketoglutarate enters the
tricarboxylic acid (TCA) cycle to manage the energy generation [110]. Therefore,
the important metabolism of glutamine through GLS1 is critical to the generation
of the neurotransmitter, glutamate, and the brain bioenergetics via the TCA
cycles.
In the physiological conditions, GLS1 is found most abundantly in neurons
and less so intense in astrocytes, microglia, and macrophages in the CNS.
However, when microglia and macrophages are activated, the level of GLS1 is
altered, which leads to the abnormal glutamate-glutamine cycle in the CNS.

1.5 The pathological role of Glutaminase 1 in HAND
Although the exact mechanisms of how HIV infection induces HAND
remains to be elucidated, the role of GLS1 has been reported to be crucial in the
pathogenesis of HAND. In the past decade, our lab has helped to determine the
neurotoxic profile of brain macrophages and microglia in cooperation with other
researchers. We have been devoted to discovering novel molecular mechanisms
and biochemical tools to understand the pathogenesis and a potential target for
treating HAND.
Our group has identified that HIV-1 infected human macrophages and
microglia express high levels of GLS1 that contribute to the production of excess
extracellular glutamate, which leads to neurotoxicity through overstimulation of
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NMDA receptors. Notably, HIV-infected macrophages and microglia show
upregulated GLS1 that produces increasing levels of glutamate dependent on
glutamine, which indicates that the increasing level of GLS1 can augment the
neuroinflammation and neurotoxicity [53, 72]. We have also reported that HIV-1infected macrophages and microglia are the major sources of increased
extracellular glutamate and that they are significantly more neurotoxic than the
uninfected macrophages and microglia [53, 111, 112]. The major upregulated
isoform of GLS1 in HIV-1-infected macrophages and microglia is GAC, both at
the RNA and protein levels, not KGA. Using siRNA to target GLS1 in HIV-1infected macrophages and microglia significantly reduces the production of
glutamate and the associated toxicity in neurons. Removing the glutamine,
antagonizing the NMDA receptor, or blocking GLS1 activity by pharmacological
GLS1 inhibitors effectively reversed the excess generation of glutamate and
neurotoxic effects from HIV-1-infected macrophages and microglia [53]. In the
samples of postmortem HAND patients’, increasing levels of glutamate and
upregulated GLS1 are found in vivo, which also proves the importance of GLS1
in the pathogenic process and disease progressions of HAND.
Mitochondrial oxidative stress is caused by the infection of HIV-1, which
mediates the release of GLS1 from the inner membrane of mitochondria to
cytosol through the permeability transition pore [111]. Interestingly, we also
detected the release of GLS1 in the extracellular media. However, the
mechanism of release of GLS1 from cytosol to extracellular media remains
unknown.
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The expression of GLS1 is usually most abundant in neurons. However,
little has been known about the role of GLS1 in mediating the excitotoxicity in
neurons associated with HAND until recently. In our laboratory, we reported that
treatment of IL-1β and TNF-α, the two proinflammatory cytokines typically
elevated during neurodegenerative conditions, on neurons induces cell apoptosis
through substantially increased intracellular and extracellular glutamate levels
[78]. The glutamate produced from these neurons under inflammation induces
toxicity in other neurons. Furthermore, IL-1β and TNF-α upregulates the
expression of the GLS isoform KGA expression in human neurons and increases
the release of KGA from the mitochondria into the cytosol. TNF-α also triggers
the release of GLS1 into the extracellular space. We also found that Interferon
α/β (IFN-α/β), generated from HIV-1-infected macrophage/microglia, activates
Signal transducer and activator of transcription 1 (STAT1) to bind with
glutaminase promoters and regulate GLS1 expressions [113]. The neurotoxicity
is reversed by the inhibition of GLS1 activity with pharmacological inhibitors or by
the blockage of NMDA receptors with antagonists.
Taken together, these results indicate the critical role of dysregulated
GLS1 in neurons, macrophages, and microglia in the pathogenesis of brain
inflammation and HAND.

1.6 Extracellular vesicles
Extracellular

vesicles

(EVs)

have

been

implicated

in

various

neurodegenerative diseases and neuroinflammation including Alzheimer’s
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disease, Parkinson’s disease, prion disease, Huntington’s disease, multiple
sclerosis, and HAND. EVs are vesicles ranging from 30 nm to 1000 nm that are
shed from various cell types including neurons, astrocytes, macrophages,
microglia, oligodendrocytes and blood endothelial cells in the CNS. EVs are
released under normal and pathological conditions. EVs are composed of
microvesicles (MVs) and exosomes, in which MVs range from 100 nm to 1000
nm while exosomes range from 30 nm to 100 nm. Biologically, MVs are believed
to be derived from the plasma membrane, while exosomes are thought to be
derived from the inward budding of the late endosomes. After budding, they are
held within multivesicular bodies, which fuse with the plasma membrane. Both
MVs and exosomes were once considered as a mechanism for discarding
cellular debris or material. However, attention has been drawn to the role of EVs
in the importance of intercellular communication and signal transduction.
Evidence has shown that EVs can carry, nucleic acids, mRNAs, and other
noncoding RNAs, proteins, cytokines and lipids among cells. Since differentiating
exosomes and MVs is still a big challenge, the entire population of secreted and
released MVs and exosomes in the extracellular milieu are all identified as EVs.
Due to the various intracellular origins and formation of EVs, the detailed
functional role of EVs under normal and disease conditions warrants further
investigation.
The biogenesis of EVs including microvesicles and exosomes is still under
investigation. Exosomes are believed to originate in the endocytic pathway,
where proteins are internalized, and are either recycled back to the plasma
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membrane or sorted for degradation [114, 115]. After internalization, early
endosomes are formed and mature into late endosomes with an inward budding
of their membrane and accumulation of intraluminal vesicles (ILVs) to form
multivesicular bodies (MVBs). MVBs either fuse with lysosomes for degradation
of their contents, or fuse with the plasma membrane to release the exosomes to
the extracellular milieu via exocytosis [116-118]. However, it remains to be
elucidated how pathway selection is determined. The biogenesis of microvesicles
also needs further investigation.
As a mixture group of proteins, lipids and other cytosolic molecules is
sorted into exosomes and microvesicles, the specific contents of EVs can vary
depending on the type of cells, the condition of the cells, and the
microenvironment niche the cells are in. There has been increasing interest in
EVs and studies have focused on building the databases of the contents of EVs
from different physiologic environments, which is continuously updated in
Exocarta, Vesiclepedia and EVpedia [119-121]. In these database, different
proteins, lipids, mRNAs, and miRNAs are identified in EVs from different cells
types and organisms by proteomics, mass spectrometry and microarray. Studies
show that EVs contain proteins from endosomes, plasma membrane, and cytosol
that are involved in MVB biogenesis, membrane associated proteins,
transmembrane proteins, cytoskeletal proteins, signal transduction proteins,
chaperones and metabolic enzyme, but few from nuclei, Golgi, endoplasmic
reticulum (ER) and mitochondria [119, 122, 123]. Among these proteins, there is
an overlap of important proteins between microvesicles and exosomes, which
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makes it a challenge to find individual specific markers. EVs are also enriched in
lipid

composition

such

as

ceramide,

cholesterol,

sphingomyelin,

and

phosphatidylserine, which provides a tool and a recipe for artificial liposome
formulation to mimic the EVs [124]. However, due to the complexity and
variability of EVs, there are still limitations to overcome in liposomes synthesis.
Additionally, miRNAs of 20-22 nucleotides have been associated with EVs.
These miRNAs target the 3’ untranslated region of specific mRNAs to inhibit their
translation, which affects the proliferation, differentiation, survival and function of
the cells [125]. Despite the variety of cellular contents in the EVs, questions
remain as to mechanisms of cargo incorporation into EVs are, and how they are
altered dependent on the cell source and the physiological or pathological
condition and microenvironment of the cells [126, 127].
EVs were believed to be a pathway to degrade unwanted cellular
contents, however, the recent hypotheses focus more on their role in cargo
delivery, and intercellular signaling, especially during immune responses [128,
129]. While more light has been shed on the role of EVs in several cancers;
however, further investigation is needed on their role in the CNS system.
Recent studies have indicated the importance of EVs in translational
research, since it is know that EVs can be detected in biological fluids, such as
blood, plasma, urine, and CSF [130-132]. It has been suggested that EVs have
been used as biomarkers for various diseases. The contents in the EVs detected
from CSF-samples reflect brain physiology, including amyloid precursor protein
(APP)

and

amyloid

β (Aβ)

in

Alzheimer’s

disease,

α-synuclein

in
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Parkinson's disease, PrPsc in prion disease, and Superoxide dismutase (SOD) in
amyotrophic lateral sclerosis.

1.7 Mechanism of extracellular vesicle release
The mechanisms of detailed differentiation of EVs is still understudied.
There are a few major hypotheses about the EV release. One of these is called
Endosomal Sorting Complexes Required for Transport (ESCRT) machinery,
which involves the ESCRT complexes and their associated proteins [133]. One of
the alternative mechanisms is the ESCRT-independent pathway. This lipid-driven
mechanism of EV release depends on the synthesis of ceramide from
sphingomyelin by neutral sphingomyelinase [134]. Another hypothesis is the
RhoA-dependent pathway, which has been suggested in EVs studies in cancer
research [135].
Despite the recent studies of the extracellular vesicles, very little is known
about the mechanisms of EV release in macrophages and microglia. The role of
GLS1 in the regulation of EVs remains to be further explored.

1.8 Conclusion
Regarding the need to better understand HAND pathogenesis, we have
learned that EVs contribute to the neuronal damage associated with
overproduction of glutamate and excitotoxicity. The critical role of EV as the
specific molecular cargo carriers and their place in intercellular communication
cannot be ignored. Previous reports from the lab have shown the importance of
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GLS1 and glutamate in HAND, and further investigation revealed the role of EVs
in the release of GLS1 and the potential neurotoxic role of EVs during HIV-1
infection and immune activation. In this case, we discovered a GLS1 inhibitor,
and we are in the process of developing new inhibitors to rescue the GLS1mediated neurotoxicity, which can be a novel therapeutic strategy.
With the heated discussion about EVs, their contents, biogenesis, delivery
and functions still require further investigations. During our study, we discovered
an interesting phenomenon in that the inhibition of GLS1 could disrupt the
formation or release of EVs to the extracellular space. This provides us with a
new perspective on the important role of GLS1 in the biogenesis of EVs. This
evidence can also be applied to the fields outside of neuroscience study, such as
cancer research due to the important role of GLS1 in both fields. This
observation can shed light on the correlation of glutamine metabolism and other
pathways including sphingolipid biogenesis in EV release, which also indicates
the importance of developing a new therapeutic strategy against EVs and GLS1.
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1.9 Figures
Figure 1.1

Figure 1.1 proposed model for the pathogenic role dysregulated GLS1 and
EVs in HAND.
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Chapter 2
HIV infection and immune activation induce neurotoxicity through GLS1containing extracellular vesicles
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2.1 Abstract
HIV-1-infected and/or immune-activated microglia and macrophages are
pivotal in the pathogenesis of HIV-1-associated neurocognitive disorders
(HAND). Glutaminase, a metabolic enzyme that facilitates glutamate generation,
is upregulated and may play a pathogenic role in HAND. Our previous studies
have demonstrated that glutaminase is released to the extracellular fluid during
HIV-1 infection and neuroinflammation. However, key molecular mechanisms
that regulate glutaminase release remain unknown. Recent advances in
understanding intercellular trafficking have identified extracellular vesicles (EVs)
as a novel means of shedding cellular contents. We posit that during HIV-1
infection and immune activation, microvesicles may mediate glutaminase
release, generating excessive and neurotoxic levels of glutamate.
EVs isolated through differential centrifugation from cell-free supernatants
of monocyte-derived macrophages (MDM) and BV2 microglia cell lines were first
confirmed in electron microscopy and immunoblotting. As expected, we found an
elevated number of EVs, glutaminase immunoreactivities, as well as glutaminase
enzyme

activity

in

the

supernatants

of

HIV-1

infected

MDM

and

lipopolysaccharide (LPS)-activated microglia when compared with controls. The
elevated glutaminase was blocked by GW4869, a neutral sphingomyelinase
inhibitor known to inhibit EV release, suggesting a critical role of EVs in
mediating glutaminase release. More importantly, EVs from HIV-1-infected MDM
and LPS-activated microglia induced significant neuronal injury in rat cortical
neuron cultures. The EV neurotoxicity was blocked by a glutaminase inhibitor or
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GW4869, suggesting that the neurotoxic potential of HIV-1-infected MDM and
LPS-activated microglia is dependent on the glutaminase-containing EVs.
These findings support EVs as a potential pathway/mechanism of
excessive glutamate generation and neurotoxicity in HAND and therefore EVs
may serve as a novel therapeutic target.
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2.2 Introduction
HIV-1-associated neurocognitive disorders (HAND) are currently prevalent
in spite of major advances in combination anti-retroviral therapy. Therefore, novel
therapeutic targets are required to be developed to treat the disease [5, 9, 71,
136]. The HIV-1-infected and immune-activated mononuclear phagocytes (MPs,
including macrophages and microglia) are critical to HAND pathogenesis,
producing a variety of inflammatory and neurotoxic factors, including excess
levels of the excitatory neurotransmitter glutamate [137, 138]. Glutamate is a
major mediator of excitatory synaptic transmission and has a vital role in
mediating learning and memory [139-141]. Early studies reported that the
concentrations of glutamate in the plasma and cerebrospinal fluid were
significantly higher in HIV-1-infected patients than in uninfected controls [142145]. Studies also showed that excessive levels of extracellular glutamate induce
excitotoxicity and augment neuroinflammation and neuronal injury, which may
play a role in the pathogenesis of HAND [74, 108, 146-149].
Glutaminase (GLS), a resident mitochondrial enzyme, is specialized in the
de novo synthesis of the neurotransmitter glutamate [42, 105, 150-152]. Two
major types of GLS exist in mammals, which include “kidney-type” GLS (GLS1)
and “liver-type” GLS (GLS2) transcribed from different genes. GLS has also been
found to be abundant in the brain tissue [108]. In the human brain, GLS1 has two
allozymes: kidney-type glutaminase (KGA) [153] and glutaminase C (GAC) [154].
The allozymes are generated through tissue-specific alternative splicing from the
same gene and have the identical core GLS1 enzyme domain but different 3’
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tails [109]. Our previous studies suggested that GAC and KGA are differentially
upregulated in HAND brain samples, HIV-1-infected MPs and inflammatory
neurons [53, 72, 78, 112, 137]. Increased extracellular levels of glutamate from
activated MPs could cause excitotoxicity to neurons through NMDA receptor
activation [53, 112]. Therefore, regulation of GLS1 isoforms is of importance to
HAND research. A key molecular event associated with the elevation of
glutamate is the release of GLS1 [72, 78, 112]. Although several early
observations of GLS1 release were linked with cell death, more recent data from
our lab suggested that mitochondrial stress could lead to membrane
destabilization and relocation of GLS1 from the mitochondrial matrix to the
cytosol through the permeability transition pore [111]. Because the further
release of GLS1 into extracellular supernatants contributes to excess glutamate
production, it is imperative to understand the molecular mechanism of cellular
GLS1 release.
Recent evidence indicates that extracellular vesicles (EVs), cellular
secretory vesicles, are shed from the plasma membrane and range from 100 nm
to 1 µm in diameter [155]. Interestingly, EVs are abundant in the central nervous
system (CNS) and are derived from multiple brain cell types, including neurons,
microglia, oligodendrocytes, and astrocytes [156]. Therefore, there is a growing
appreciation of the important role of EVs in regulating the brain microenvironment
[157, 158]. CNS-derived EVs may contribute to neuroinflammation through
secretion of signaling molecules, nucleic acids, lipids, and proteins, and may
participate in inter- and intra-cellular communication [155, 159-164]. The release
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of EVs is increased upon neural cancer progression, neuroinflammation, and
acute neurological disorders [165-167]. EVs could serve as a useful biomarker
for CNS diseases including ischemic stroke, multiple sclerosis, glioblastoma, and
other neurological and neurodegenerative disorders. However, the role of EVs in
the pathogenesis of neurodegenerative disorders, especially HAND, remains to
be elucidated. In our current study, we identified EVs as a primary mechanism of
GLS1 release, which subsequently mediates excess glutamate generation and
neurotoxicity from HIV-1-infected macrophages and immune-activated microglia.
The investigation of the function of GLS1-containing EVs is important for
understanding a potentially pathological event in HAND, and it may provide
possible therapeutic targets and a unique biomarker.
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2.3 Materials and methods
Culture, HIV-1 infection and LPS activation of macrophages and microglia
Human peripheral blood-derived mononuclear cells were isolated through
leukopheresis from healthy donors. Human macrophages were differentiated in
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO)
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma),
and 1,000 U/ml recombinant human macrophage colony-stimulating factor
(MCSF) for 7 days. The HIV-1ADA strain was used to infect the macrophages and
microglia at a multiplicity of infection (MOI) of 0.1 and 0.5, respectively. The HIV1ADA strain was originally isolated from the PBMCs of an HIV-infected patient with
Kaposi’s sarcoma [168, 169]. MDM was infected with HIV-1ADA at a multiplicity of
infection (MOI) of 0.05 virus/target cell. For mock-infection, MDM was incubated
with the same volume of medium without the virus. After 24 hours, the culture
medium was changed to remove any remnant virus. Seven days after HIV-1infection, the culture medium was changed to glutamine-free neurobasal medium
for 24 h and supernatants were collected for subsequent RT-HPLC or Western
blot analysis. BV2 cell lines were obtained from ATCC, and both cell lines were
grown in DMEM with 10% fetal bovine serum and antibiotics. Lipopolysaccharide
(LPS) (50 ng/ml) (Sigma) was used to immune activate BV2 cells for 24 h and
supernatants were collected for HPLC and Western blot analysis.

Rat cortical neuron cultures

26
Cerebral cortices were dissected from Sprague-Dawley rat (Charles River
Laboratories International Inc., Wilmington, MA) between embryonic days 15 and
17 and triturated with a pipet to generate cell suspension. The cell suspension
was passed through a 70-µm nylon membrane (Becton Dickinson Labware,
Franklin Lakes, NJ) and then plated at a density of 40,000 cells/well in 96-well
plates pre-coated with 5 µg/ml poly-D-lysine. The cells were then cultured at
37 °C in a 5% CO2 atmosphere for 7 days in neurobasal medium containing B27
supplement (Life Technologies), 0.5 mM glutamine, 100 U/ml penicillin and 100
µg/ml streptomycin.

Ethics statement
Primary rat cortical neuron (RCN) were prepared in accordance with
ethical guidelines for care and use of laboratory animals set forth by the National
Institutes of Health (NIH), with Institutional Animal Care and Use Committee
(IACUC) #: 04-097-01; Monocytes were used in full compliance with the
University of Nebraska Medical Center and NIH ethical guidelines, with the
Institutional Review Board (IRB) #: 162-93-FB. We have the informed written
consent from all participants involved in this study.

Isolation of EVs
EVs were isolated from the supernatants of HIV-1-infected macrophages
and LPS-activated microglia through differential centrifugations with or without
neutral sphingomyelinases inhibitor GW4869 (Sigma) at different dosages, 2, 5
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and 10 µM. Briefly, the supernatants were first centrifuged at 300 X g for 10 min
to remove free cells, at 3,000 X g for 20 min to remove cellular debris and then
10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected by
ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western blot,
the EVs pellets were lysed in M-PER mammalian protein extraction reagent
(Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were fixed in 2%
glutaraldehyde and 2% paraformaldehyde. For glutaminase activity assay and
neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free neurobasal
medium.

Negative staining and electron microscopy
EVs were negatively stained with onscreen measurements. Briefly, EVs were
fixed and then spread on the silicon monoxide and nitro-cellular film coated
copper grid. The droplets of EVs were removed with filter paper, air-dried at room
temperature and then subjected to transmission electron microscopy (TEM) (FEI
Tecnai G2 Spirit TWIN). For the scanning electron microscope (SEM) (FEI
Quanta 200), cells were fixed in 2% glutaraldehyde and 2% paraformaldehyde
and point dried, mounted and coated with gold/palladium. The investigator in the
EM core facility was blinded for image acquisition and quantification.

Neurotoxicity assays
Resuspended EVs were added to neuronal cultures for 48 h with or without 10
µM of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a
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generous gift presented by Dr. Tsukamoto from Colorado State University) and
cell viability was assessed by MTT assays in 96-well plates. MTT (Sigma) was
added to the cultures to a final concentration of 125 µg/ml. The plates were
incubated for 30 minutes at 37 °C with 5% CO2 and the medium was aspirated.
The insoluble formazan was solubilized in DMSO, and the concentrations were
determined by optical density at 490 nm with an ELX808 densitometer (Bio-Tek
Instruments, Winooski, and VT). MAP2 ELISA was performed on primary RCN
cultures as previously described. Briefly, fixed neurons were blocked with 3%
normal goat serum in phosphate buffered saline and incubated for 2 hours with
antibodies against microtubule associated protein 2 (MAP-2) (Millipore-Chemicon
International, Atlanta, GA), followed by the anti-mouse biotinylated antibody
(Vector Laboratories, Burlingame, CA) for 1 hour. Avidin/biotin complex solution
was added for 30 minutes, and then color was developed using TMB substrate
(Sigma Chemical Co., St. Louis, MO) and terminated with 1 M sulfuric acid
(Sigma Chemical Co., St, Louis, MO). The absorbance was read at 450 nm using
a microplate reader (Bio-Rad Laboratories, Hercules, CA). For morphological
data that demonstrated neuronal damage after exposed to the supernatant of
HIV-1-infected

macrophages

or

immune-activated

microglia,

MAP2

immunostaining was examined by a Nikon Eclipse TE2000E fluorescent
microscope and photographed by a digital camera (CoolSNAP EZ, Photometrics).
All obtained images were imported into Image-ProPlus, version 7.0 (Media
Cybernetics, Sliver Spring, MD) for quantifying levels of MAP2 staining. The
assessors were blinded during image acquisition or quantification.
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Western blot
Protein concentrations were determined by Bradford protein assay. SDS PAGE
separated proteins from whole cell and EV lysates. After electrophoretically
transferred to polyvinyldifluoridene membranes (Millipore, Billerica, MA and BioRad, Hercules, CA).

Membranes were incubated overnight at 4 °C with

polyclonal antibodies for GAC (Dr.N.Curthoys, Colorado State University, Fort
Collins, CO), Alix (Santa Cruz Biotechnology, CA) and flotillin-2 (Cell Signaling
Technology, Danvers, MA), followed by horseradish peroxidase-linked secondary
anti-rabbit or anti-mouse secondary antibodies (Cell signaling Technology).
Antigen-antibody complexes were visualized by Pierce ECL Western Blotting
Substrate. For quantification of the data, films were scanned with a CanonScan
9950F scanner and images were analyzed using the public domain NIH image
program (developed at the U.S. National Institutes of Health and available on the
internet at http://rsb.info.nih.gov/nih-image/).

Analysis of glutamate and glutamine by RP-HPLC
Glutamate levels were analyzed by reverse phase high performance liquid
chromatography (RP-HPLC) using an Agilent 1200 liquid chromatograph and
fluorescence detector as previously described [53] with a few modifications. The
experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse AAA analytical
columns (Agilent). A gradient elution program was optimized for glutamate
measurement with a flow rate 0.75 ml/min.
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Statistical analysis
Data are expressed as means ± SD unless otherwise specified. Statistical
analysis was performed using Analysis of variance (ANOVA), followed by the
Tukey-post-test for paired observations. Significance was determined by a p
value < 0.05. All experiments were performed with cells from at least three
donors to account for any donor-specific differences. Assays were performed at
least three times in triplicate or quadruplicate within each assay.
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2.4 Results
HIV-1 infection and immune activation increase EV release from
macrophages and microglia
Our previous studies have demonstrated that GLS1 is released to the
extracellular fluid during HIV-1 infection and neuroinflammation [72, 78, 112].
However, key molecular mechanisms that regulate GLS1 release remain
unknown. The recent discovery of EVs during HIV-1 infection in macrophages
and dendritic cells offers an exciting possibility that GLS1 may be released
through EV mechanism [155, 170]. We used scanning electron microscopy (SEM)
to identify EVs that were in the process of budding from macrophages (Fig. 2.1A,
B). To quantitatively evaluate EV release, two different techniques for EV
detection were used. First, EVs were isolated from cultured monocyte-derived
macrophages (MDM) supernatants by differential centrifugation. To reflect the
changes of EVs from the same number of cells, EVs were isolated from
normalized volumes of supernatants based on the protein concentrations in the
whole cell lysates. Cells, nuclei, debris and subcellular organelles were removed
from the supernatant after serial centrifugation. The EV pellet was collected and
resuspended for negative staining under transmission electron microscopy (TEM).
Images of EVs from ten random fields were captured. The numbers of EVs per
field under TEM was significantly higher in HIV-1-infected macrophages than
EVs from mock-infected macrophages, suggesting that HIV-1 infection leads to
increased release of EVs in MDM (Fig. 2.1C-E). Second, EVs isolated from
infected human macrophages were subjected to Western blots for specific EV
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markers, including ALG-2 interacting protein (Alix) and flotillin-2. Consistent with
TEM data, Western blot analysis revealed increased levels of Alix and flotillin-2 in
EV lysates from HIV-1-infected cells, compared with those from uninfected
cultures (Fig. 2.1F, G). Western blot also showed intact levels of voltagedependent anion channels (VDAC) from whole cell lysates. Absence of VDAC
from EV lysates was confirmed to exclude contamination of mitochondria in
isolated EVs (Fig. 2.1H).
Similarly, when murine microglia cell line BV2 was treated with
lipopolysaccharide (LPS) for immune activation, the EV number was significantly
higher in the LPS-treated EV2 compared with the untreated group (Fig. 2.2A-C).
The increased release of EVs from LPS-treated EV2 cells was further confirmed
by Western blot detecting EV markers, Alix and flotillin-2 (Fig. 2.2D, E). Because
EVs were isolated from normalized volumes of supernatants based on their
corresponding whole cell protein concentrations, a higher number of EVs in TEM
and increased immunoreactivities of EV markers in Western blots from HIV-1infected macrophages and LPS-stimulated microglia suggest that HIV-1 infection
and immune activation both increase EV release from the cultures.

EVs mediate GLS1 release in HIV-1-infected MDM and immune-activated
microglia
To determine whether EVs are the main mechanism for GLS1 release in
HIV-1-infected MDM and immune-activated microglia, we treated the cultures
with GW4869, a neutral sphingomyelinases (nSMase) inhibitor, for 24 hours prior
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to EVs isolation. GW4869 is known to disrupt in the biogenesis of EVs by
inhibiting the generation of ceramide [134, 171]. Because GW4869 was
dissolved in DMSO, we used DMSO as a solvent control for GW4869 and used
the same amount of DMSO in each dose of the GW4869 treatment. EV markers,
Alix and flotillin-2, were both increased in the EVs isolated from HIV-1-infected
MDM (Fig. 2.3A-C). Pretreatment with GW4869 for 24 hours reduced the levels
of Alix and flotillin-2 in the EVs isolated from HIV-1-infected MDM, indicating the
increased EV release in HIV-1-infected MDM could be blocked by GW4869 (Fig.
2.3A-C). The protein levels of GAC, a GLS1 isoform previously identified to have
neurotoxic potential, were also increased in EVs after HIV-1 infection and
diminished after GW4869 treatment, indicating that EVs carried GAC as cargo
and that HIV-1 increases GAC release through EVs (Fig. 2.3A, D). Supernatants
were collected from the mock-infected, HIV-1-infected with or without GW4869
and subjected to RT activity assay. The results indicated that after seven days of
HIV-1 infection, the treatment of GW4869 with different concentration did not
affection the HIV-1 virus replication, indicating GW4869 is inhibiting the release
of EV through a mechanism other than lowering HIV-1 infection (Fig. 2.3E).
Consistent with HIV-1 infection, LPS activation of microglia line BV2 cells
also lead to increased EV secretion (Fig. 2.4A-C). After treatment with increasing
concentrations of GW4869, the increase of Alix and Flotillin-2 in the EVs isolated
from LPS-activated microglia was blocked, suggesting that immune activation
also increases EV release in microglia (Fig. 2.4A-C). Importantly, GAC protein
levels were also increased in EVs after LPS activation and diminished after
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GW4869 treatment, confirming that immune activation also increases GAC
release through EVs (Fig. 2.4A, D).

EVs isolated from HIV-1-infected MDM and immune-activated microglia
mediate extracellular glutamate production through GLS1
The identification of EVs in mediating GAC release raises the question of
the functional relevance of GAC to EVs. HIV-1 infection is known to increase
extracellular levels of glutamate in human macrophages [71]. We treated cell-free
HIV-1-infected supernatants with 5 mM glutamine, the reaction substrate for
GLS1 enzyme, in the presence of 6-Diazo-5-oxo-L-norleucine (L-DON), a GLS
inhibitor. The levels of glutamate production, as determined by RT-HPLC,
increased after HIV-1 infection, which was dependent on glutamine (Fig. 2.5A).
Furthermore, the elevation of glutamate was blocked by L-DON, indicating that
the released GLS1 promotes glutamate generation in the extracellular fluid of
HIV-1-infected MDM (Fig. 2.5A). More importantly, EV pellets extracted from both
mock- and HIV-1-infected MDM were directly tested for GLS1 activity by HPLC.
EVs were incubated with neurobasal media with or without glutamine for two
days. Interestingly, the levels of glutamate generated in EVs from HIV-1-infected
cultures elevated significantly compared with mock-infected control (Fig. 2.5B).
Low-speed pellets were collected after 10,000 g centrifugation, which may
contain subcellular organelles and debris. Interestingly, blockage of GLS1 activity
by L-DON was only observed in the EVs but not in the low-speed pellets from
HIV-1-infected MDM, suggesting that EVs are the specific compartments for
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GLS1 release and responsible for excess glutamate production (Fig. 2.5B). To
further investigate how EVs facilitate glutamine hydrolysis through the GLS1, we
determined the level of vesicular glutamate transporter (VGLUT) in the EV
lysates from HIV-1 infected MDM through Western blots (Fig. 2.5C, D). VGLUT
levels increased after HIV-1 infection and decreased after GW4869 treatment,
consistent with the overall EV levels. These results indicate VGLUT is a
component of EVs and suggest that glutamate transporters on the EV lipid
bilayer may facilitate the transportation of glutamate. Consistent with HIV-1infected MDM, EVs isolated from the supernatant of LPS-stimulated microglia
significantly increased glutamate generation, which could be blocked by L-DON
(Fig. 2.6A). Taken together, these data suggest that GLS1 released through EVs
in HIV-1-infected MDM and immune-activated microglia maintains enzyme
activity and promotes glutamate generation.

GLS1-containing EVs induce neurotoxicity
To investigate the functional significance of GLS1-containing EVs from
HIV-1-infected MDM and immune-activated microglia, EVs were collected and resuspended in the neuronal culture medium. The volumes of culture medium used
to re-suspend EVs were adjusted based on the whole cell protein concentration
in the same culture. Rat cortical neurons (RCN) treated with 1 µl, 10 µl or 100 µl
per well of EVs from mock-infected MDM didn’t show significant neurotoxicity
(Fig. 2.7A, B). However EVs extracted from HIV-1-infected MDM had significantly
lower viabilities (Fig. 2.7C) and higher neurotoxicity (Fig. 2.7E) compared with
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those treated with EVs from mock-infected cells. However, the EV-induced
toxicity was rescued at the presence of BPTES, a GLS1 inhibitor, when 100 µl of
EVs were incubated with RCN (Fig. 2.7D, F). When RCN was treated with 100
ng/ml of soluble receptor for TNF, the toxicity induced by EVs from HIV-1infected MDM was not rescued, which suggests the toxicity is not affected
through TNF-α (Fig. 2.7G). Interestingly, the toxicity was rescued by the
application of MK801, an uncompetitive agonist of N-Methyl-D-Aspartate (NMDA)
receptor, indicating the toxicity of GLS1-containing EVs was through the
excitotoxicity via glutamate (Fig. 2.7H).
Similarly, EVs from control BV2 cells didn’t show any neurotoxicity (Fig.
2.8A), but neurotoxicity was observed in neurons treated with EVs isolated from
LPS-activated microglia in a volume-dependent manner (Fig. 2.8B). This toxicity
was blocked by BPTES (Fig. 2.8C). Interestingly, RCN didn’t demonstrate toxicity
when treated with EV free supernatants collected after EV isolation (Fig. 2.8D),
indicating the toxicity was majorly induced via EVs. These data suggest that the
GLS1-containing EVs induce neurotoxicity through the GLS1 activity in the EVs.

HIV-1-infected MDM induce neurotoxicity through GLS1-containing EVs
To determine whether HIV-1-infected MDM induce neurotoxicity through
GLS1-containing

EVs,

we

obtained

supernatants

from

HIV-1-infected

macrophages that were pre-treated with 2, 5 or 10 µM of GW4869 and used the
supernatants to treat RCN for neurotoxicity. Similar to prior experiments, we used
DMSO as a solvent control for GW4869 and used the same amount of DMSO in
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each dose of the GW4869 treatment. Neurotoxicity was determined through
quantifications of neuronal antigen MAP2 with either MAP2 ELISA (Fig. 2.9A) or
MAP2

immunostaining

(Fig.

2.9B-H).

The

HIV-1-infected

MDM-induced

neurotoxicity was blocked by increasing concentrations of GW4869 (Fig. 2.9),
indicating that supernatants from HIV-1-infected MDM induce neurotoxicity
through EVs. Next, we isolated EVs from mock-infected and HIV-1-infected MDM
and investigated the direct neurotoxicity of EVs. Interestingly, EVs isolated from
HIV-1-infected MDM manifested higher levels of neurotoxicity as determined by
MAP2 ELISA (Fig. 2.10A) or MAP2 immunostaining (Fig. 2.10C-I), when
compared with EVs from mock-infected control. However, the EV-free
supernatants did not show any toxicity from the indication of MAP2 ELISA (Fig.
2.10B). Treatment of GW4869 prior to EV isolation rescued EV-induced
neurotoxicity at a dose dependent manner, suggesting a direct neurotoxic role of
EVs from HIV-1-infected MDM. Together, these data strongly suggest that HIV-1infected macrophages induce neurotoxicity through EVs.
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2.5 Discussion
Our previous reports have described the release of GLS1 into extracellular
space during neuroinflammation or HIV-1 infection. However, key molecular
mechanisms that regulate GLS1 release remain unknown. Our current study
presents two important new findings regarding the GLS1 release. First, EVs
contain GLS1, which is a key enzyme for generating glutamate in the brain, and
GLS1 is released into the extracellular fluid primarily via EVs in HIV-1-infected
cells and immune-activated microglia. Second, HIV-1 infection and LPS
activation increase the magnitude of EV release from macrophages and
microglia. Interestingly, increased release of GLS1-containing EVs also induces
excitotoxicity in RCN. The toxic effect of EVs was reversed by glutaminase
inhibitors and EV inhibitors. These observations suggest that EVs may contribute
to excess glutamate production in macrophages in the context of HIV-1
neurotoxicity.
The physiological relevance of this observation is significant, where
elevated endogenous levels of GLS1 have been reported in the post-mortem
brain tissues of HIV-1-associated dementia patients [53, 113]. Furthermore, it
has been demonstrated that both of the upregulated GLS1 isoforms, KGA and
GAC, are released from the inner membrane of mitochondria into the cytosol
through the permeability transition pore [72, 111]. However, it is the extracellular
glutamate that causes neurotoxicity, and the mechanisms by which cytosolic
GLS1 is released into the cell supernatant have not been previously established.
The current study provides strong evidence that GLS1-containing EVs are the
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main mechanism for the release of GLS1 from the macrophage and microglia
cytosol into the extracellular compartment, where the extracellular glutamate
subsequently induces neurotoxicity. It is unclear how GLS1 hydrolyzes
extracellular glutamine inside EVs. We have detected vesicular glutamate
transporter in the EV lysates from HIV-1 infected MDM (Fig. 2.5), suggesting that
EVs may transport glutamate across its lipid bilayer through glutamate
transporters.
Our studies were designed to rigorously establish the purity and
characterization of the isolated microvesicles. To confirm complete separation of
EVs from mitochondria, the absence of the mitochondrial marker protein voltagedependent anion-selective channel (VDAC) and cytochrome C was confirmed
through Western blots. Secondly, to characterize the EVs, both scanning and
transmission electron microscopies were used, which showed vesicles ranging in
size from 50 nm to 500 nm. Western blot could not detect the presence of GLS1
in exosomes collected from commercially available exosome kits, suggesting that
GLS1 is selectively packed into the larger form of EVs rather than into smaller
exosomes. Furthermore, because the EV-free supernatants and the pellets that
contained cellular debris had minimum GLS1 activities and GLS1 was found
predominantly in the isolated EVs fraction, we concluded that EVs are the
primary instigator in facilitating GLS1 release in HIV-1-infected macrophages and
LPS-activated microglia.
Chronic activation of the immune system is a hallmark of progressive HIV
infection yet its etiology remains obscure. Circulating microbial products such as
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LPS, possibly derived from the gastrointestinal tract, was significantly increased
in chronically HIV-infected individuals and may be a cause of HIV-related
systemic immune activation [172]. In our report, when LPS was used to treat BV2
microglia cell line, high levels of GLS1 were found in the supernatants leading to
neurotoxicity. These results support the pathogenic effect of the immune
activation in the CNS during HIV-1 infection. The discovery that GLS1
upregulation induces GLS1 release via EVs may have a broader implication to
other neurological diseases, where excitotoxicity and GLS1 are involved.
Because EVs are abundantly expressed in the CNS, it is tempting to speculate
whether qualitative or quantitative changes of EVs contribute more broadly to
neurological diseases. In addition, the regulation of EVs could be exploited as a
novel therapeutic target.
In the current study, we also utilized an EV inhibitor, GW4869, to block the
release of the EVs. Both GLS1 and EV markers were decreased in a dosedependent manner by GW4869, suggesting that GLS1 release is through EVs.
GW4869 is an inhibitor for nSMase2, which is responsible for the production of
ceramide. Ceramide has been found enriched in EVs and involved in the
formation of vesicles. Our results point to a possible mechanism of EVs release
in the microglia and macrophages through the endosomal sorting complex
required for transport (ESCRT) machinery or a ceramide-dependent pathway
[134, 171]. These interesting possibilities remain the subject of future
investigation. Furthermore, we have demonstrated that the neurotoxicity by HIV1-infected MDM was abolished by pre-treatment with GW4869, which indicates
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that GLS1-containing EVs are the neurotoxic factors in HIV-1-infected
macrophages and immune-activated microglia. Therefore, inhibiting the release
of EVs might become a potential therapeutic approach for the treatment of HAND
patients.
Three aspects of the studies merit further investigation. First, how is
cytosolic GLS1 loaded into EVs for extracellular secretion from macrophages?
Second, how are GLS1-containing EVs formed? Third, what mediates the
release of GLS1-containing EVs from the plasma membrane? Autophagosomes,
inflammasomes

or

mitochondria-derived

vesicles

may

provide

possible

mechanisms for these events to occur. It is possible that HIV-1 infection and
immune activation of macrophages and microglia directly lead to the release of
GLS1-containing EVs, however, other possibilities also need to be explored.
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2.6 Conclusion
In summary, our studies address important questions regarding the
cellular mechanisms of GLS1 release, implicating a critical role of EVs. This
newfound knowledge of neurotoxic GLS1-containing EVs has potentially
important clinical implications for neurologic diseases such as HAND. Developing
inhibitors of EV formation and release or inhibitors of GLS1 might yield effective
new therapies for reducing glutamate-induced neurotoxicity in HIV-1-infected and
immune-activated individuals.
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2.7 Figures
Figure 2.1
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Figure 2.1 HIV-1 infection increases EVs release from macrophages.
(A) MDM was fixed at 7th day post HIV-1 infection and subsequently subjected
to SEM for EV detection. Magnification, 6000 X. (B) High-magnification image of
the corresponding small box area in panel A was shown. Magnification, 24000 X.
(C-E) eVs were isolated through differential centrifugation from normalized
volumes of cultural supernatants and observed under TEM using negative
staining. Representative TEM images of EVs from mock-infected MDM (C), HIV1 infected MDM (D) were shown. (E) EVs numbers in C and D were quantified by
manually counting from a total of 10 random vision fields. Results are
representative of TEM images and quantification results are means ± SD of EV
numbers from 10 fields of TEM images. ** denotes p < 0.01 in comparison to
controls. (F) EVs were isolated from normalized volumes of supernatants in
mock-infected and HIV-1-infected MDM cultures. The levels of Alix and flotillin-2
in EVs were determined by Western blot. (G) Densitometric quantifications of the
Alix and flotillin-2 protein levels were presented as fold change relative to the
untreated controls. (H) The level of mitochondrial marker, voltage-dependent
anion channels (VDAC) was detected in both whole cell and EV lysates to
exclude contamination in EVs.
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Figure 2.2
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Figure 2.2 Immune activation increases EVs release from microglia.
(A-B) EVs were isolated through differential centrifugation from normalized
volumes of cultural supernatants and observed under TEM using negative
staining. Representative TEM images of EVs from untreated microglia (A), and
LPS-stimulated microglia (B) were shown. (C) EVs numbers in C, D and E, F
were quantified by manually counting from a total of 10 random vision fields.
Results are representative of TEM images and quantification results are means ±
SD of EV numbers from 10 fields of TEM images. ** denotes p < 0.01 in
comparison to controls. (D) EVs were isolated from normalized volumes of
supernatants in untreated and LPS-stimulated microglia cultures. The levels of
Alix and flotillin-2 in EVs were determined by Western blot. (E) Densitometric
quantifications of the Alix and flotillin-2 protein levels were presented as fold
change relative to the untreated controls.
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Figure 2.3
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Figure 2.3 EVs mediate GLS1 release in HIV-1-infected MDM.
(A) At 7 days post-infection, mock-infected and HIV-1 infected MDM were treated
with GW4869 for 24 hours in serum-free media. EVs were isolated from the
supernatants and EV protein lysates were prepared. The levels of Alix, flotillin-2,
and GAC were determined by Western blots. (B-D) Densitometric quantifications
of the Alix (B), flotillin-2 (C), and GAC (D) protein levels were presented as fold
change relative to the mock-infected controls. (E) Supernatants were collected
and subjected to RT activity assay. DMSO was used as solvent control for
GW4869. Western blot results shown are representative of three independent
experiments. Quantification results shown are means ± SD of experiments
performed in triplicate (n = 3 donors). ** and *** denotes p < 0.01 and 0.001 in
comparison to mock-infected or untreated control; #, ## and ### denote p < 0.05,
0.01 and 0.001 in comparison to HIV-infected or immune-activated groups,
respectively.
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Figure 2.4
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Figure 2.4 EVs mediate GLS1 release in immune-activated microglia.
(A) EVs were isolated from the supernatants of control and LPS-treated
microglia in the presence and absence of GW4869. EV lysates were subjected to
Alix, flotillin-2, and GAC detection through Western blots. Results shown are
representative of three independent experiments. (B, C, D) Densitometric
quantifications of the Alix (B), flotillin-2 (C), and GAC (D) protein levels were
presented as fold change relative to the untreated controls. DMSO was used as
solvent control for GW4869. Western blot results shown are representative of
three independent experiments. Quantification results shown are means ± SD of
experiments performed in triplicate (n = 3 donors). ** and *** denotes p < 0.01
and 0.001 in comparison to mock-infected or untreated control; #, ## and ###
denote p < 0.05, 0.01 and 0.001 in comparison to HIV-infected or immuneactivated groups, respectively.
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Figure 2.5
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Figure 2.5. EVs isolated from HIV-1-infected MDM mediate extracellular
glutamate production through GLS1.
(A) Cell-free supernatants from mock-infected and HIV-1-infected macrophages
were incubated with or without glutamine and 1 mM L-DON ex vivo for two days.
The resulting glutamate levels were determined by RP-HPLC. *** denotes p <
0.001 in comparison to the 5 mM glutamine group in HIV-1-infected samples. (B)
EVs were isolated from cell-free supernatants from mock-infected and HIV-1infected MDM and incubated with or without glutamine and 1 mM L-DON ex vivo
for two days. Glutamate generation in EVs or low speed (LS) pellets was
determined by RP-HPLC. Low-speed pellets were collected after 10,000 g
centrifugation, which contained subcellular organelles and debris. (C) At 7 days
post-infection, mock-infected and HIV-1 infected MDM were treated with
GW4869 for 24 hours in serum-free media. EVs were isolated from the
supernatants and EV protein lysates were prepared. The levels of vGluT were
determined by Western blots. (E) Densitometric quantifications of vGluT protein
levels were presented as fold change relative to the mock-infected controls.
Western blot results shown are representative of three independent experiments.
Quantification results shown are means ± SD of experiments performed in
triplicate (n = 3 donors). *** denotes p < 0.001 in comparison to 5 mM glutamine
group in HIV-1-infected samples or mock-infected control; ### denotes p < 0.001
in comparison to HIV-infected.
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Figure 2.6
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Figure 2.6 EVs isolated from immune-activated microglia mediate
extracellular glutamate production through GLS1.
(A) EVs were isolated from cell-free supernatants from untreated and LPSactivated microglia and incubated with or without glutamine and 1 mM L-DON ex
vivo for two days. Glutamate generation in EVs was determined by RP-HPLC. ***
denotes p < 0.001 in comparison to 5 mM glutamine group in LPS-activated
samples. Results are means ± SD of triplicate samples and are representative of
three independent experiments. *** denotes p < 0.001 in comparison to 5 mM
glutamine group in LPS-treated samples.
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Figure 2.7
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Fig

2.7.

GLS1-containing

EVs

from

HIV-1-infected

MDM

induce

neurotoxicity.
EVs were isolated from both mock-infected and HIV-1-infected MDM at 7 days
post-infection. EVs were resuspended in neuron medium. Different volume of 0,
1, 10 and 100 µl of EVs from mock-infected (A, B) and HIV-1-infected (C) MDM
were added to the RCN and incubated for 24 hours. 100 µl of EVs from mockinfected and HIV-1-infected MDM were added in RCN with or without 10 µM of
BPTES, a GLS1 inhibitor, neutralizing TNF-α antibody or MK801 for 24 hours (C,
F, G, H). Neurotoxic potentials of EVs were determined by MTT (C, D) and MAP2
ELISA assays (E, F). *, ** and *** denote p < 0.05, 0.01 and 0.001 in comparison
to controls, respectively; #, ## and ### denote p < 0.05, 0.01 and 0.001 in
comparison to HIV-infected group, respectively. Results are expressed as means
± SD of triplicate samples and are representative of three independent
experiments.
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Figure 2.8
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Fig 2.8. GLS1-containing EVs from immune activated microglia induce
neurotoxicity.
(A-D) EVs were isolated from BV2 microglia cells treated with LPS overnight.
EVs were resuspended in neuron medium. Different volume of 0, 1, 10 and 100
µl of EVs from control BV2 cells without LPS treatment (A) and LPS-treated (B)
BV2 were added to the RCN and incubated for 24 hours. 100 µl of EVs were
added in RCN with or without 10 µM of BPTES, a GLS1 inhibitor, for 24 hours (C).
EV free supernatants after differential centrifugation were also collected and 100
µl of supernatants were added to RCN with or without 10 µM of BPTES for 24
hours. Neurotoxic potentials of EVs were determined by MTT (A, B, D) and
MAP2 ELISA assays (C). * and *** denote p < 0.05 and 0.001 in comparison to
controls, respectively; ### denotes p < 0.001 in comparison to LPS-treated group,
respectively. Results are expressed as means ± SD of triplicate samples and are
representative of three independent experiments.
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Figure 2.9
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Fig 2.9. HIV-1-infected macrophages induce neurotoxicity through GLS1containing EVs.
At 7 days post-infection, mock-infected and HIV-1 infected macrophages were
treated with GW4869 at different dosages for 24 hours. Cell-free supernatants
and EVs were collected and added to RCN cultures for neurotoxicity. DMSO was
used as solvent control for GW4869. (A, B) Neurotoxic potentials of the
supernatants were determined by MAP2 ELISA assay (A) and quantification of
MAP2 fluorescence in immunostaining (B). (C-H) Neurotoxic potentials of
supernatants with EVs were determined by MAP2 immunostaining followed by
quantification of the intensity of MAP2 fluorescence after EVs treatment (B). *
and *** denote p < 0.05 and 0.001 in comparison to mock-treated control,
respectively ; ## and ### denote p < 0.01 and 0.001 in comparison to DMSOpretreated HIV-infected group, respectively. Results are expressed as means ±
SD of triplicate samples and are representative of three independent experiments.
Results are representative of 20 fluorescent images from three independent
experiments.
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Figure 2.10
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Figure 2.10. HIV-1-infected macrophages induce neurotoxicity through
GLS1-containing EVs.
At 7 days post-infection, mock-infected and HIV-1 infected macrophages were
treated with GW4869 at different dosages for 24 hours. Cell-free supernatants
and EVs were collected and added to RCN cultures for neurotoxicity. DMSO was
used as solvent control for GW4869. (A, B) Neurotoxic potentials of EV (A) and
EV free supernatants (B) were determined by MAP2 ELISA assay. (C-I)
Neurotoxic potentials of EVs were determined MAP2 immunostaining (C-H)
followed by quantification of the intensity of MAP2 fluorescence after EVs
treatment (I). * and *** denote p < 0.05 and 0.001 in comparison to mock-treated
control, respectively ; ## and ### denote p < 0.01 and 0.001 in comparison to
DMSO-pretreated HIV-infected group, respectively. Results are expressed as
means ± SD of triplicate samples and are representative of three independent
experiments. Results are representative of 20 fluorescent images from three
independent experiments.
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Chapter 3
GLS1 are involved in the release of extracellular vesicles in activated
macrophages and microglia
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Abstract
Extracellular

vesicles

(EVs)

are

important

in

the

intercellular

communication in the central nervous system. Their release is increased during
neuroinflammation and neurological disorders. Our previous data demonstrated
an increased release of EVs from HIV-1-infected macrophages, and that these
EVs have neurotoxic effects. However, the mechanism of elevation of EV release
in those HIV-1-infected cells remains unknown. In our current study, we
investigated glutaminase 1 (GLS1), which is a mitochondrial enzyme critical for
glutamine metabolism. GLS1 is upregulated in HIV-1-infected macrophages and
microglia. We propose that HIV-1 infection increases GLS1, leading to a
metabolic status that favors the EVs generation and release. This new
understanding of the metabolic control of EV release in HIV-1-infected cells will
shed light on HIV-1 pathobiology and neurological complications.
Cultures of human primary microglia and monocyte-derived macrophages
culture system and macrophage-tropic HIV-1ADA were used to study the
regulation of EVs during HIV-1 infection. EVs were isolated through differential
centrifugations. A gene overexpression system, delivered via adenovirus vector,
was utilized to overexpress GLS1 in the cell culture to mimic the upregulation of
GLS1 during HIV-1 infection. A brain-specific GLS1 transgenic mouse line was
created to model GLS1 elevation in vivo. BPTES was used to specifically inhibit
GLS1 activity. Transmission electron microscopy and Western blot were used to
quantify the EVs released from cells and brain tissues. Glutamate and glutamine
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levels

were

determined

by

reverse

phase

high-performance

liquid

chromatography.
An elevated number of EVs was found in the supernatants of HIV-1infected

macrophages

and

microglia

when

compared

with

controls.

Overexpression of GLS1 in macrophages and microglia cultures lead to
increased release of EVs. Conversely, blocking the GLS1 activity by BPTES
significantly reduced EV release and glutamate generation in HIV-1-infected
macrophages and microglia, suggesting a critical role of GLS1 in EV release.
Interestingly, we detected an elevated release of EVs in the brain tissues of
GLS1 transgenic mice, suggesting that GLS1 is also important for EV release in
vivo.
GLS1 is essential for EVs release in HIV-1-infected macrophages and
microglia. Therefore, blocking EV release through GLS1 inhibitors may serve as
a novel therapeutic strategy against the HIV-1 pathobiology and neurological
complications.
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3.1 Introduction
Glutaminase 1 (GLS1) is a metabolic enzyme located on the inner
membrane of mitochondria, which deaminases glutamine into glutamate. GLS1
is known to be associated with cancer cell research and CNS disease [53, 173,
174]. GLS1 is the predominant glutamine-utilizing enzyme in the CNS, where
GLS2 is expressed at a lower level [175].
In the past decade, our lab has focused on understanding the role of
GLS1 in the brain using molecular and chemical tools. We have reported that
GLS1 plays a role in microglia and macrophages and later in neurons during
brain inflammation and injury [53, 112]. During HIV-1 infection and immune
activation, glutamate level is excessively increased due to the upregulation of
GLS1 [53, 72, 112, 149]. The elevated glutamate levels have been associated
with the neuronal injury and excitotoxicity in various CNS disorders [102, 176,
177]. Interestingly, the upregulation of GAC in the postmortem brain tissue of
HAND patients was identified [53, 112]. Recently, we also reported that
extracellular vesicles (EVs) contain GLS1 from HIV-1infected macrophages and
immune-activated microglia. We also reported that these EVs induce toxicity in
neurons [178].
EVs are secretary vesicles derived from either cell membranes or
multivesicular bodies that range from 50 nm up to 500 nm. In physiological
conditions, EVs facilitate the cell-to-cell interactions between neurons and glial
cells through the transfer of the neurotransmitter cargos. EVs have lipid bilayers,
which protect their cargos from degradation via proteases and RNases [135, 155,
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160]. However, in response to stress, such as DNA damage, hypoxia, exposure
to viruses or bacteria, the release of EVs increases and the contents within the
EVs alter as well. As EVs can be detected in a variety of biological fluids such as
plasma and cerebral spinal fluid (CSF), they are prime candidates for biomarkers
of diseases [167].
EVs have been detected at an elevated level in the cerebral spinal fluid in
patients with mild to severe AD, PD, prion disease and ALS [163, 179]. More
importantly, protein markers of EVs are present in neuritic plaques in AD brains.
This evidence suggests that EVs play a potential role in the pathogenesis of
neurodegenerative diseases and neuroinflammation. Moreover, the defective
metabolism of sphingolipids in the brain has been associated with EV release.
Studies have reported that sphingolipids are increased in different regions of AD
brains and may promote Aβ biogenesis [180]. Studies have shown that the
neutral sphingomyelinase (nSMase) inhibitor, GW4869 significantly reduces the
release of EVs and its neurotoxicity in HAND and AD [178, 180]. However, upon
all evidence, it remains unclear what the mechanism of EV regulation is.
Aside from in vitro models, our lab has developed a new mouse line to
overexpress GAC in the mouse brain to mimic the pathogenesis during HAND,
which is competitive with the other available murine models for HAND, including
HIV-1 glycoprotein 120 (gp120) transgenic mouse, the HIV-1 encephalitic (HIVE)
mouse, HIV-Tat transgenic mouse and the humanized mouse [181], [182-184].
However, none of these HAND models was able to demonstrate the role of GLS1
in the pathogenesis of HAND. The successful generation of the GAC-
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overexpressing mice demonstrates an increase of brain inflammation, neuronal
damage and learning and memory deficits. This mouse model also provides a
strong in vivo tool to study the role of GLS1 in EV regulation.
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3.2 Materials and Methods
Culture, HIV-1 and LPS infection of macrophages and microglia
Human peripheral blood-derived mononuclear cells were isolated through
leukopheresis from healthy donors. Human macrophages were differentiated in
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO)
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma),
and 1,000 U/ml recombinant human macrophage colony-stimulating factor
(MCSF) for 7 days. Human fetal microglial cells were obtained from fetal brain
tissue-derived microglia-astrocytes mixed cultures as previously described [185].
The HIV-1ADA strain was used to infect the macrophages and microglia at a
multiplicity of infection (MOI) of 0.1 and 0.5, respectively. After 24 hours, culture
medium was changed to remove any remnant virus. Seven days after HIV-1infection, culture medium was changed to glutamine-free neurobasal medium for
24 h and supernatants were collected for subsequent HPLC or Western blot
analysis. HeLa and BV2 cell lines were obtained from ATCC, and both cell lines
were grown in DMEM with 10% fetal bovine serum and antibiotics.
Lipopolysaccharide (LPS) was used to immune activate BV2 cells for 24 h and
supernatants were collected for HPLC and Western blot analysis. Bis-2-(5phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a generous gift
presented by Dr. Tsukamoto from John Hopkins and later ordered from Millipore)
at a concentration of 10 µΜ were added to HIV-1-infected macrophages or LPStreated microglia prior to EV isolation. All experiments involving human cell
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samples are approved by Institutional Review Board of University of Nebraska
Medical Center.

GAC-overexpressing mice
Mouse Gac gene was selected and cloned from a C57 mouse cDNA
library. The Gac gene was then inserted into the pCAG-Loxp-STOP-Loxp-IRESLacZ plasmid at restriction enzyme site Xhol. The plasmid was constructed and
sequenced specially for forwardly inserted Gac. The linearized plasmid was
selected and microinjected into the fertilized eggs for the further implantation into
a pseudopregnant female to create CAG-loxp-GAC mouse in the Mouse
Genome Engineering Core Facility of UNMC. The stability of the constructed
plasmid was examined through visualizing the GFP expression in the CAG-lloxpGAC mice brains. Four weeks old nestin promoter-driven cre transgenic mice
(Nestin-Cre mouse) line was purchased from Jackson laboratory (Bar Harbor,
ME), where the cre activity is only restricted to CNS. The CAG-loxp-GAC mice
were then mated with Nestin-Cre mice. Nestin-GAC mice were produced and the
absence of GFP was examined to ensure the success of the generation of GACoverexpressing mice. Similarly, Thy-1 promoter-driven cre transgenic mice were
used to mate with the CAG-loxp-GAC mice to generate Thy-1-GAC mice. DNA
was extracted from embryonic tissue or adult mouse tail tissue with
phenol/chloroform. DNA was then purified using isopropanol and ethanol. PCR
reactions were conducted to genotype all transgenic mice. All mice were housed
and bred in the Comparative Medicine facilities of the University of Nebraska
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Medical Center. All procedures were conducted according to protocols approved
by the Institutional Animal Care and Use Committee of the University of
Nebraska Medical Center.

Morris Water Maze (MWM) test
The training phase and probe phase are the two major parts in MWM test.
Mice were introduced into a 91 cm circular water tank, which was equally divided
into four quadrants. Visual cues were placed around the pool to direct mice to the
submerged 10 cm circular platform. A variety of parameters were recorded to
evaluate the movement of the mice. For each trial, the mouse was given 60
seconds to find the submerged platform before guided to the platform. Each
mouse completed four trials per day during a 5-day training phase. On the 6th day,
the probe test was conducted. The platform was removed and each mouse was
given 60 seconds to swim in the tank. The parameters were videotaped and
analyzed by Ethovision XT (Noldus, Netherlands).

Contextual Fear Conditioning (CFC) test
Contextual fear conditioning test was performed following standard
protocols in the light- and sound-attenuated chambers for mouse (Coulbourn Tru
Scan Activity Monitoring System for mouse). On the 1st day of the test, mice were
allowed to habituate in the clean chamber for 300 seconds without any
stimulation. On the 2nd day, the chamber was scented with 0.1% acetic acid and
the mice were given two electric shocks at 170 s and 290 s via automated Tru
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Scan Stimulus. On the 3rd day, the chamber was scented with 0.1% acetic acid
without shock stimulus. Mice in the chamber were recorded for 180 s. Mouse
behavior was evaluated under ambient illumination (room light) and was
recorded by a SAMSUNG digital videocamera above the chamber. The behavior
recorded was analyzed by Ethovision XT by assessing the time of freezing.

Preparation of adenovirus overexpressing glutaminase
KGA and GAC were cloned into a Shuttle Vector and Replication-defective
adenovirus vectors expressing human KGA and GAC were generated by the
RAPAd® Adenoviral Expression System (Cell Biolabs, Inc. San Diego, CA 92126)
following the manufacturer’s instruction. Adenoviral constructs were amplified in
a 293AD cell line (Cell Biolabs, Inc) and purified by ultracentrifugation through a
CsCl gradient. Quantification of the adenoviral infectious unit was performed
using Adeno-X™ Rapid Titer Kit (Clontech Laboratories, Inc. Mountain View, CA
94043). HeLa cells, BV2 cells, or primary human microglia were infected at a
multiplicity of infection of 50. Cells were used for experiments 2 days after
infection.

Isolation of EVs from cells
EVs were isolated from the supernatants of GLS1-overexpressing cells,
HIV-1-infected macrophages and LPS-activated microglia through differential
centrifugations. Briefly, the supernatants were first centrifuged at 300 X g for 10
min to remove free cells, at 3,000 X g for 20 min to remove cellular debris and

73
then 10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected
by ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western
blotting, the EV pellets were lysed in M-PER mammalian protein extraction
reagent (Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were
fixed in 2% glutaraldehyde and 2% paraformaldehyde. For glutaminase activity
assay and neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free
neurobasal medium.

Isolation of MVs from mice brain
EV isolations from the brains were carried out as described previously with
modifications according to the protocol [186]. Fresh and previously frozen mice
hemibrains were harvested and dissected finely. Brain samples were then
treated with 20 units/ml papain (Worthington) in Hibernate E solution (BrainBits,
Springfield, IL) for 15 minutes at 37 °C. The same volume of cold Hibernate E
solution was added to the brains samples to stop the reaction of papain. The
brain tissue was then gently homogenized and filtered through a 40-µm mesh
filter (BD Biosciences), followed by a centrifugation at 300 X g for 10 min and,
3000 X g for 20 min at 4 °C to get rid of cells, membranes and debris. After the
supernatants were filtered through 0.45 µm filter (Thermo Scientific), they were
subjected to 10, 000 X g for 30 min at 4 °C to eliminate organelles
contaminations. The supernatants were further centrifuged at 100, 000 X g for 70
min at 4 °C to pellet EVs. The pellets were then resuspended in filtered PBS, or
MPER lysate solution for Nanosight or Western blot. All the samples were
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ultracentrifuged in ultraclear polycarbonate tubes (Beckman Coulter) that have a
volume of 13.2 ml. A Beckman Coulter ultracentrifuge (Beckman Coulter
OptimaL-90K ultracentrifuge; Beckman Coulter, Fullerton, CA, USA) was used
with a rotor type 41 wi.

Negative staining and electron microscopy
EVs were fixed and then spread on the silicon monoxide and nitro-cellular
film coated copper grid. The droplets were removed with filter paper, air-dried at
room temperature and then subjected to transmission electron microscopy (TEM).
For scanning electron microscope (SEM), cells were fixed in 2% glutaraldehyde
and 2% paraformaldehyde and point dried, mounted and coated with
gold/palladium.

Nano-particle tracking analysis
NanoSight NS 300 (Malvern) equipped with an sCMOS camera was utilized to
analyze the size distribution and concentration of EVs. NanoSight utilizes
Nanoparticle Tracking Analysis (NTA), which is a combination of light scattering
and Brownian motion to measure the concentration and size distribution of
particles in the EV supernatants. After the whole process of EV isolation, the
pellets were first resuspended in 100 µl of filtered PBS and then diluted by 100
times. The conditions of the measurements include a temperature of 25 °C,
viscosity of 1 cP, 25 seconds per capture frame and a measurement time of 60 s.
All the conditions were kept the same among all the samples. The results
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indicate the mean sizes and concentration of at least three individual
measurements.

Toxicity/MTT/MTS assays
GLS1 inhibitors were added to HIV-1-infected macrophage or LPSactivated microglia cultures and cell viability was assessed by MTT assays in 24well or 96-well plates.

MTT (Sigma) was added to the cultures to a final

concentration of 125 µg/ml. The plates were incubated for 30 minutes at 37 °C
with 5% CO2 and the medium was aspirated. The insoluble formazan was
solubilized in DMSO, and the concentrations were determined by optical density
at 490 nm with an ELX808 densitometer (Bio-Tek Instruments, Winooski, and
VT). Alternatively, Celltiter aqueous one solution cell proliferation assay, which
contains

a

novel

tetrazolium

compound

[3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) was
utilized to assess cell viability according to the manufacturer instruction. Briefly,
20 µl of reagent was added into a 100 µl of culture medium, and then incubated
the plates in a humidified, 5% CO2 and 37 °C atmosphere for 1 hour. The
absorbance was determined at 490 nm.

Western blot
Protein concentrations were determined by Bradford protein assay. SDS
PAGE

separated

proteins

from

whole

cell

and

EVs

lysates.

After

electrophoretically transferred to polyvinyldifluoridene membranes (Millipore,
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Billerica, MA and Bio-Rad, Hercules, CA). Membranes were incubated overnight
at 4 °C with polyclonal antibodies for KGA and GAC (Dr.N.Curthoys, Colorado
State University, Fort Collins, CO), tissue transglutaminase (tTG) (Lab
Vision/Thermo, Fremont, CA), flotillin-2 (Cell Signaling Technology, Danvers, MA)
and β-actin (Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidaselinked secondary anti-rabbit or anti-mouse secondary antibodies (Cell signaling
Technology). Antigen-antibody complexes were visualized by Pierce ECL
Western Blotting Substrate. For quantification of the data, films were scanned
with a CanonScan 9950F scanner and images were analyzed using the public
domain NIH image program (developed at the U.S. National Institutes of Health
and available on the internet at http://rsb.info.nih.gov/nih-image/).

Glutaminase activity assay
Highly concentrated whole cell lysates were collected from flasks and
subjected to GLS activity assay using a two-step assay [187, 188]. Briefly,
protein concentrations in the lysates were tested by using BCA Protein Assay Kit
(Pierce). All samples were normalized to same concentration. In the first step,
fifty milligrams of protein was added to 100 µL of initial assay mix. The mix
contains 50 mM glutamine, 0.15 M phosphate, 0.2 mM EDTA, and 50 mM trisacetate. The PH value of the mix was adjusted to 8.6 and incubated at 37 °C for
30 min. 10 µL of 3 N hydrochloric acid (HCl) was added to inactivate the
glutaminase activity and stop the reaction. In the second step, 1 mL of the
second reaction mix was added, which contained 0.4 mg of purified bovine liver
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glutamate dehydrogenase (Sigma-Aldrich, St. Louis, MO, USA), 0.08 M Trisacetate at pH 9.4, 0.2 M hydrazine, 0.25 mM ADP (adenosine 5'-diphosphate
sodium salt), and 2 mM NAD (β-nicotinamide adenine dinucleotide hydrate). The
samples were mixed and incubated for 30 min at room temperature. 100 µL of
reaction was used for measurement and absorbance was determined at a
wavelength of 340 nm, glutamate concentration was determined using a
standard curve of 10, 5, 2.5, 1.25, 0.625, and 0.0 mM glutamate, along with
negative controls.

Analysis of extracellular glutamate and glutamine by RP-HPLC
Glutamate levels were analyzed by RP-HPLC using an Agilent 1200 liquid
chromatograph and fluorescence detector as previously described [14] with a few
modifications. The experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse
AAA analytical columns (Agilent). A gradient elution program was optimized for
glutamate measurement with a flow rate 0.75 ml/min.

Analyses of intracellular glutamate concentrations
The intracellular glutamate levels in whole brain lysates of mice and whole
cell lysates were determined by Amplex Red Glutamic acid/Glutamate Oxidase
Assay Kit (Invitrogen) based on the manufacturer’s instruction. Brain tissue
lysates and whole cell lysates were diluted to the same protein concentration
before the assay.
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Statistical analysis
Data are expressed as means ± SD unless otherwise specified. Statistical
analysis was performed using one way ANOVA, followed by the Tukey-post-test
for paired observations or two way ANOVA using Bonferroni post-tests to
compare replicate means. Significance was determined by a p value < 0.05. All
experiments were performed with cells from at least three donors to account for
any donor-specific differences. Assays were performed at least three times in
triplicate or quadruplicate within each assay.
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3.3 Results
GLS1 overexpression increases EVs release in vitro.
The

molecular

mechanism(s)

for

EV

release

in

HIV-1-infected

macrophages remain unclear. Our previous reports showed that GLS1 was
upregulated and caused increased glutamate production in HIV-1-infected
macrophages [112]. To further study the mechanism of GLS1 and EV release,
we constructed adenovirus vectors that overexpressed KGA or GAC to mimic the
upregulation of these isoforms during HIV-1 infection. The extracellular levels of
glutamate increased significantly in both KGA- and GAC-overexpressing HeLa
cells at the multiplicities of infection (MOI) of 200 compared with uninfected or
vector-treated cells (Fig. 3.1A). An MOI of 200 was then used for the following
GLS1-overexpression experiments. The overexpression of KGA and GAC were
confirmed by Western blot (Fig. 3.1B). GLS1 enzyme activity assay confirmed
increased KGA and GAC activity in concentrated protein lysates from KGA- and
GAC-overexpressing HeLa cells, suggesting that the overexpressed KGA and
GAC were functional (Fig. 3.1C). Furthermore, protein lysates were utilized to
test the intracellular glutamate. The level of glutamate was increased after KGAand GAC-overexpression compared with GFP and control group (Fig. 3.1D).
Consistently, supernatants were collected from each group and cell debris was
removed. Samples were subjected to RP-HPLC after acid and base treatment to
determine

the

extracellular

level

of

glutamate.

Both

KGA

and

overexpression showed increased glutamate in the supernatants (Fig. 3.1E).

GAC
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Next, we looked at GLS1 activities in the extracellular fluid of the KGAand GAC-overexpressing HeLa cells. Previously, we reported that GLS1 was
released from the inner membrane of mitochondria in the cytosol in HIV-1infected macrophages [111]. However, whether elevation of GLS1 levels induces
GLS1 translocation or release remains unclear till we proved that GLS1 activity
was previously detected in the EVs [178]. Consistently, using KGA and GAC
overexpression, cell-free supernatants showed increased glutamate production
after addition of glutamine. Furthermore, GLS1 inhibitor, L-DON, blocked the
excess generation of glutamate in the overexpression supernatants, indicating
that GLS1 activity was present in the extracellular supernatants from KGA- and
GAC-overexpressing HeLa cells (Fig. 3.2A). To confirm that glutaminase is
released from cytosol to extracellular space via EVs in GLS1 overexpression,
EVs were collected from cell-free supernatants and tested for glutaminase
activity. EVs that were isolated from KGA- or GAC-overexpressing HeLa cells
generated significantly higher levels of GLS1 when incubated with glutamine (Fig.
3.2B). When L-DON was added to the enzyme reactions, the generation of
glutamate was blocked, suggesting that KGA- and GAC-overexpression induced
EVs release that contain high levels of GLS1 activities (Fig. 3.2B). Due to the
limited protein extracted from EVs, extracellular glutamate level was measured
using RP-HPLC to test the levels of GLS1 activities instead of the traditional
GLS1 activity enzyme assay. Furthermore, proteins from EVs showed increasing
EV markers, tTG and flotillin-2 in KGA- and GAC-overexpressing HeLa cells with
elevated expression of KGA and GAC in the lysates of MVs (Fig. 3.2C-E).
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However, the level of EV markers in the whole cell lysates did not change (Fig.
3.2C-E). Together, these data suggest that elevation of GLS1 is sufficient to
induce the extracellular release of GLS1-containing EVs.

Inhibition of GLS1 activity reduces EVs release in HeLa cells.
When treated with EGF, HeLa cells release more EVs to the extracellular
fluid [189]. Moreover, EGF has been reported to increase the activity of GLS1.
Therefore, the increase of GLS1 activity by EGF triggers the EVs from HeLa cells
indicated that the alteration of GLS1 could be a potential mechanism of EVs
release. To investigate the effect of the GLS1 inhibitors on GLS1 level in whole
cells, and to further explore the impact of GLS1 inhibitor on EV release, both 10
µM BPTES, 30 µM carbenoxolone (CBX) or 100 µM L-DON were treated 24 hr
prior to EV isolation. EVs were collected through differential centrifugation and
lysed for Western blot. To compare the amount of EV released, the concentration
of whole cell lysates was measure to normalize to the volume of EVs according
to the concentration of whole cells. The level of EV markers, flotillin-2 and CD9,
were decreased under Western blot, indicating a potential inhibition of EV
release by the GLS1 inhibitors compared with the endogenous levels of GLS1 in
HeLa cells (Fig. 3.3 E-G). This evidence suggests that blocking GLS1
significantly reduces the release of EVs in HeLa cells.

Inhibition

of

GLS1

activity

reduces

EV

macrophages and immune-activated microglia.

release

in

HIV-1-infected
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In HIV-1-infected macrophages or immune-activated microglia, GLS1
expression is upregulated and EV release is increased [178]. To further
investigate whether GLS1 inhibitor can affect the level of EV release in
macrophages, human macrophages were infected with HIV-1 virus with 10 µM
BPTES prior to harvest or 5 µM Atazanavir (AZT) on the second day of infection.
Whole cell lysates were collected to detect the expression level of the GLS1
isoform, GAC. The treatment of AZT, which inhibits the HIV-1 viral replication,
significantly decreased the level of GAC that was upregulated during HIV-1
infection. The addition of BPTES in HIV-1-infected macrophages didn’t reduce
the protein level of GAC (Fig 3.4A, B). Interestingly, when BPTES was added
one day after HIV-1 infection, or one day prior to EV isolation, EV lysates showed
a decreased level of EV markers, Flotillin-2 and tTG from HIV-1-infected
macrophages. However, when BPTES was added immediately after the HIV-1
infection, the result of EV release was not affected, indicating BPTES affect the
EV release in a short-term manner (Fig 3.4C-F).
To test the effect of GLS1 inhibitors on microglia, we used a murine
microglial cell line, BV2 and human microglia cells. When GLS1 inhibitors, 10 µM
BPTES, or 10 µM CB839 were added to BV2 cells 4 hours prior to LPS treatment
for overnight, GLS1 inhibitors did not reduce cell viability (Fig. 3.5A). The results
from GLS enzyme activity assay showed an increased GLS activity in the LPSactivated BV2 cells but a decreased GLS activity with the treatment of BPTES
and CB839 (Fig 3.5B). The inhibition of the GLS activity in LPS-stimulated BV2
cells is stronger in the group treated with CB839 than the group treated with
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BPTES. Both whole cell lysates and EV lysates were collected and subjected to
Western blot. The ratio of GAC to β−actin showed no significant change.
However, EV markers in the EV lysates showed an increase trend after LPS
treatment and a decrease trend after the treatment of BPTES and CB839 (Fig
3.5C-G). When the EVs were isolated, PBS priorly filtered through 0.22 µm
PVDF filter was used to resuspend EV pellets and 10 µl EV was added to 990 µl
PBS. One hundred times diluted EVs were then subjected to nanoparticle
tracking analysis. LPS treatment group showed an increased EV particle
concentration from BV2 cells. Interestingly, the treatment of BPTES and CB839
both reduce the EV concentrations, which is consistent to the results in Western
blot (Fig 3.5B).
To further verify this effect in human microglia, EVs were isolated from
LPS-treated human microglia with or without BPTES. Both EV markers, Flotillin-2
and CD9 showed an increased level of EV release after LPS treatment but a
decrease after 10 µM BPTES treatment (Fig 3.6A-C).
Consistently, these results indicated that GLS1 inhibitors block the release
of EVs in HIV-1-infected macrophages and LPS-treated microglia.

Brain-specific GLS1 overexpression increases EVs release in vivo.
To further investigate the release of EVs in vivo, Nestin-GAC and wild type
(WT) were generated by crossing Nestin-Cre mice and CAG-loxp-GAC mice and
PCR reactions were performed to confirm the genotypes of the mice (Fig. 3.7A).
To first confirm the changes in behaviors that are related to the learning and
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memory functions, Nestin-GAC mice of 8 weeks old and control littermates were
first subjected to Morris-Water-Maze (MWM) test and Cued-Contextual Fear
Conditioning (CFC) test. During MWM test, Nestin-GAC mice tended to spend
more time and travel a longer distance to reach the target platform and the speed
of swimming didn’t change compared with WT control from training phase to
probe test. Overall, the Nestin-GAC mice had fewer crossings over the platform
area when the platform was removed on the probe test day than WT control (Fig
3.7B). Interestingly, in the CFC test, Nestin-GAC mice showed less freezing in
the percentage compared with WT control on the probe test day (Fig 3.7C).
These results indicate that Nestin-GAC mice have impaired learning and memory
related to hippocampal and cortical functions. After the behavioral tests, groups
of mice were sacrificed, half of the brain of each mouse was subjected to EV
isolation, and the other half was lysed to extract total proteins. The proteins from
the kidney of both Nestin-GAC mice and the WT control mice were also collected
as controls. The protein levels of GAC in the brain from Nestin-GAC mice were
significantly higher than that from control littermates (Fig 3.7D, E). Intracellular
glutamate levels were higher in Nestin-GAC brain lysates but the same in the
kidney, indicating GAC overexpression is only limited to the mouse brain (Fig
3.7F). Furthermore, proteins were extracted from different regions of the brains of
Nestin-GAC mice and WT control. The levels of intracellular glutamate were
consistently higher in the hippocampus, cortex, midbrain and cerebellum (Fig
3.7G). Altogether, these results confirmed the GAC overexpression in the Nestin-
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GAC mouse brain and demonstrated significant learning and memory deficits
that are similar to the HAND model.
EVs were isolated and purified from hemibrains of both WT and NestinGAC mice through the specifically developed/modified protocol [186]. The
expression levels of EV markers, Alix and Flotillin-2 were both increased using
Western blot from Nestin-GAC mice compared with WT mice (Fig. 3.8A-C).
Similarly, EVs extracted from Thy1-GAC mice, which is another breed of GAC
overexpressing mouse model, were also increased compared with WT control
using negative staining by TEM (Fig.3.8D-F). Excitingly, these data indicate that
the brain-specific GAC overexpression increases EVs release in vivo.
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3.5 Discussion
Chronic neuroinflammation is a hallmark in the pathogenesis of
neurodegenerative diseases including HAND, Alzheimer’s disease, Parkinson’s
disease, multiple sclerosis and amyotrophic lateral sclerosis [48, 49, 51, 86]. HIVinfected or immune activated macrophages and microglia play a pivotal role in
brain inflammation and neuronal injury through the release of various soluble
neurotoxic factors including glutamate [49, 71, 74, 78, 190].
We have previously reported that the upregulation of GLS1 in activated
macrophages and microglia significantly induce neurotoxicity through the excess
production of glutamate [53, 72, 112]. It is also reported that the mitochondrial
GLS1 was translocated from the inner membrane of mitochondria to the cytosol
upon the oxidative stress induced by HIV-infection or immune activation.
Furthermore, the release of GLS1 from cytosol to extracellular milieu was proven
to be dependent on EVs, which induce excitotoxicity in neurons [178]. However,
a remaining key question is how the EVs are formed, released and regulated.
The study in this chapter presents two major findings regarding EV release. First,
the upregulation of GLS1 induces increasing release of EVs in HIV-1-infected
and immune-activated macrophages and microglia. Second, the increasing
release of EVs in GAC-overexpressing mice is associated with the learning
impairment and neuronal injury. These observations suggest that GLS1 could be
a key component in the regulation of EV release, which could be essential in the
mechanism study of EVs.
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The pathogenic role of GLS1 in neurodegeneration has been closely
associated with clinical implications. Dysregulation of GLS1 has been reported
not only in the pathogenesis of HAND, but also in cancer proliferation and
metastasis. The increasing release of GLS1 could be crucial in causing the
prolonged brain inflammation, increased neuronal injury and worsening disease
progression in HAND. GLS1 is a key enzyme in the glutamine metabolism, where
glutamate is produced and functions in glutamate signaling and synaptic
plasticity [191-195]. The dysregulation of GLS1 causing the aberrant release of
glutamate is strongly associated with the memory loss and learning deficits due
to disrupted functioning of NMDA receptors [194-196]. The impaired glutamate
transporter in the neighboring astrocytes to take up extra glutamate during HIV-1
infection further emphasizes the essential pathogenic role of GLS1 [87, 88].
Taken together, the neurotoxic role of GLS1-containing EVs raised more
attention to the study.
To further study the role of GLS1, a new adenovirus was constructed to
overexpress both GLS1 isoforms to mimic the upregulation of GLS1 during HIV-1
infection or immune activation. Both KGA- and GAC- overexpressing HeLa cells
displayed significantly increased GLS1 enzyme activity. Together with the
increasing levels of intracellular and extracellular glutamate, the GLS1
overexpression in vitro was proven successfully. Due to low protein concentration
and low yield of EVs, it is difficult to conduct GLS enzyme activity assay. Instead,
EVs were collected from GLN-free supernatants and incubated with or without
GLN or GLS1 inhibitor. The glutamate level is measured by RP-HPLC, which can
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also provide the indication of GLS1 activity in the EVs. GLS1 activity was
detected in both the supernatants and EVs portions from the KGA- and GACoverexpressing HeLa cells. Furthermore, an increasing level of EV markers, tTG
and flotillin-2 were detected using Western blot. The absence of mitochondrial
markers, cytochrome c, VDAC, GM130, PMP70, and Calreticulin exclude the
contamination of mitochondria, Golgi, peroxisomes, and ER in the EVs after
isolation. Interestingly, when HeLa cells were treated with GLS1 inhibitor, BPTES,
CBX and CB839, the release of EVs were significantly reduced. Similar results
were also observed in the HIV-1-infected macrophages and LPS-treated
microglia when GLS1 inhibitors were added. That release of EVs was reversed
by the GLS1 inhibitors suggests that the level of GLS1 regulates the release of
EVs.
Aside from the evidence in vitro, we also generated a novel mouse model
to overexpress GAC in vivo, which demonstrated upregulated GLS1 and
elevated glutamate in the whole brain, hippocampus, cortex, midbrain, and
cerebellum.

The

mice

also

displayed

increased

reactive

astrogliosis,

neuroinflammation and learning and memory deficits. We also found that the
release of EVs is consistently increased in two GAC-overexpressing models,
Nestin-GAC and Thy1-GAC mice. However, it needs to be further investigated
whether GLS1 inhibitors can block the EV release in vivo and whether the
blocking

of

EVs

in

GAC-overexpressing

neuroinflammation and neuronal injury.

can

attenuate

the

elevated
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Further investigation is needed to elucidate the mechanism of how GLS1
is regulating the EVs. It is also unclear whether the level of GLS1 in the EVs
affects the regulation of EV release. By inhibiting GLS1 activity, CBX has been a
newly discovered GLS1 inhibitor that can reduce the release of EVs (manuscript
in preparation). Because the GLS1 is important in the glutamine metabolism and
EVs have been reported to be associated with sphingolipids, including ceramide,
it is possible that GLS1 is regulating the EV release through both metabolisms
and their connection in this regulation.
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3.6 Conclusion
In summary, the studies in this chapter address the importance of GLS1 in
the regulation of EVs, which implicate a crucial role of GLS1. Our new
understanding of how GLS1 regulates the release of EVs in vitro and in vivo has
a potential clinical implication in neurologic diseases such as HAND and
neuroinflammation and also cancer research. The effective inhibition of EV
release using GLS1 inhibitors sheds lights on developing potential therapeutic
targets in GLS1-EVs related diseases.
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3.7 Tables and Figures
Figure 3.1
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Figure 3.1. Both KGA and GAC are successfully overexpressed by
adenovirus in vitro.
(A) Cell-free supernatants were collected from adenovirus-infected HeLa cell
cultures at the MOI of 10, 50 and 200. RP-HPLC were used to determine the
extracellular glutamate level. (B) GLS1 was overexpressed through adenovirus
vectors that express KGA and GAC isoforms in HeLa cells at a multiplicity of
infection (MOI) of 200. Two days after adenovirus infection, proteins lysates were
collected from whole cells and the levels of KGA, GAC, tTG and flotillin-2 were
determined by Western blot. Actin was used as loading control. (C) Protein
lysates were collected from KGA- and GAC-overexpressing HeLa cells at the
MOI 200. GLS1 activities were determined by the enzyme activity assay. GFP
adenovirus Ad-GFP was used as vector control. (D, E) Extracellular and
intracellular glutamate levels from adenovirus-KGA and -GAC infected HeLa cells
with MOI 200 were detected by Amplex Red Glutamic acid/Glutamate oxidase
Assay Kit and RT-HPLC, respectively. Quantification results shown are means ±
SD of experiments performed in triplicate (n = 3 donors). *** and **** denotes p <
0.001and 0.0001, compared with the Ad-GFP group.
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Figure 3.2
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Figure 3.2. KGA and GAC overexpression increase EV release in vitro.
(A) Cell-free supernatants from control (CTL), Ad-GFP, Ad-KGA and Ad-GAC
infected HeLa cells were incubated with or without 5 mM glutamine (Gln) and 1
mM L-DON ex vivo for two days. The glutamate levels were determined by RPHPLC. (B) EVs were isolated from cell-free supernatants from four different
groups of HeLa cells and incubated with or without 5 mM glutamine (Gln) and 1
mM L-DON ex vivo for two days. Glutamate production from EVs was determined
by RP-HPLC. (C) Protein lysates were prepared from the whole cell lysates and
EVs pellets. The levels of EVs markers, tTG and flotillin-2 were analyzed by
Western blot. EVs protein loading was normalized with protein concentrations in
whole cell lysates. Mitochondrial marker, cytochrome c, was used as a control to
exclude contamination of EV pellets. (D, E) Densitometric quantifications of the
protein levels in EVs were presented as fold change relative to that in control EV
lysate. The protein levels in whole cell lysates were presented as fold change
relative to β-actin in whole cells. Western blot results shown are representative of
three independent experiments. Quantification results shown are means ± SD of
experiments performed in triplicate (n = 3 donors). *, ** and *** denotes p < 0.05,
0.01 and 0.001, compared with the Ad-GFP group.
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Figure 3.3.
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Figure 3.3. Inhibition of glutamine metabolism reduces EVs release in vitro.
(A) Hela cells were treated with BPTES and L-DON for 24 hours. Protein lysates
were prepared from the EVs pellets in control and GLS1 inhibitor-treated Hela
cells. The levels of EVs markers, flotillin-2 and CD9 were analyzed by Western
blot. EVs protein loading was normalized with protein concentrations in whole cell
lysates. (B, C) Densitometric quantifications of the protein Levels were presented
as fold change relative to that in control EV lysate. Western blot results shown
are representative of three independent experiments. Quantification results
shown are means ± SD of experiments performed in triplicate (n = 3 donors). *,
** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of the control
Hela cells.
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Figure 3.4
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Figure 3.4. Inhibition of glutamine metabolism reduces EVs release in HIV1-infected macrophages. Mock-infected or HIV-1-infected macrophages were
treated with 10 µM BPTES 24 h prior to harvest or treated with 10 µM AZT. (A)
Whole cell lysates were collected and GAC was measured using Western blot.
(B) Densitometric quantification of the protein level of GAC in whole cell lysates
was presented as fold change relative to β−actin. (C) EVs were isolated from
mock-infected or HIV-1-infected macrophages treated with 10 µM BPTES at the
day after infection or one day prior to EV isolation. EVs protein loading was
normalized with protein concentrations in whole cell lysates. EV markers, Alix,
flotillin-2, and tTG were measured using Western blot. (D-F) Densitometric
quantifications of the protein levels of in EV markers were presented as fold
change relative to that in mock-infected control EV lysates. Western blot results
shown are representative of three independent experiments. Quantification
results shown are means ± SD of experiments performed in triplicate (n = 3
donors). *, ** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of
the control microglia cells. # and ### denotes p < 0.05 and 0.001 compared with
that of the HIV-1-infected macrohphages.
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Figure 3.5
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Figure 3.5. Inhibition of glutamine metabolism reduces EVs release in
immune-activated microglia.
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM
medium when GLS1 inhibitors were added. (A) Cell viability was measured after
overnight treatment using MTS assay. (B) Protein lysates were collected from
LPS-treated BV2 cells with or without GLS1 inhibitors. GLS1 activities were
determined by the enzyme activity assay. (C, D) Protein lysates were prepared
from whole cell and EV pellets in control, LPS-treated and LPS-treated with
GLS1 inhibitor BV2 cells. The levels of GAC in whole cells, EVs markers, Alix
and flotillin-2 in EVs were analyzed by Western blot. EVs protein loading was
normalized with protein concentrations in whole cell lysates. PMP70, LAMP-1,
and VDAC were also measured in the whole cell and EV lysates to exclude
contaminations. (E-G) Densitometric quantification of the protein level of GAC in
whole cell lysates was presented as fold change relative to β−actin.
Densitometric quantifications of the protein levels of in EV markers were
presented as fold change relative to that in control EV lysates. (H) Quantifications
of the NanoSight NTA of vesicle concentration for samples from control, LPStreated, LPS-treated with BPTES and LPS-treated with CB839 groups. Western
blot results shown are representative of three independent experiments.
Quantification results shown are means ± SD of experiments performed in
triplicate (n = 3 donors). * and ** denotes p < 0.05 and 0.01, compared with that
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of the control BV2 cells. # denotes p < 0.05 compared with that of the LPStreated BV2 cells.
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Figure 3.6
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Figure 3.6. Inhibition of glutamine metabolism reduces EVs release in
immune activated human microglia.
(A) Human microglia were treated with or without 10 µM BPTES 4 h prior to LPS
activation. Microglia media was changed to serum-free DMEM medium when
BPTES were added. EVs were isolated and normalized depending on whole cell
concentrations. EV markers, flotillin-2 and CD9 were measured using Western
blot. (B, C) Densitometric quantifications of the protein levels of in EV markers
were presented as fold change relative to that in mock-infected control EV
lysates. Western blot results shown are representative of three independent
experiments. Quantification results shown are means ± SD of experiments
performed in triplicate (n = 3 donors). *, ** and *** denotes p < 0.05, 0.01 and
0.001, compared with that of the control microglia cells. # and ### denotes p <
0.05 and 0.001 compared with that of the LPS-treated microglia cells.
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Figure 3.7
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Figure 3.7. GAC overexpression is confirmed in Nestin-GAC mouse.
(A) The scheme shows the generation of Nestin-GAC transgenic mouse to
specifically overexpress GAC in the CNS. A plasmid vector was engineered to
overexpress GAC and then was microinjected into the fertilized egg. The egg
was implanted in the uterus of a pseudopregnant female to create CAG-loxpGAC mouse. CAG-loxp-GAC mice were mated with Nestin-Cre mice to produce
Nestin-GAC mice. (B) Morris-Water-Maze test was performed to determine the
spatial learning and memory of Nestin-GAC mice. After 5 days of the training
phase, the probe test was conducted on the 6th day. Nestin-GAC mice spent
significantly less time in the target quadrant and had fewer crossings of the target
place. (C) The Cued-Fear-Conditioning test was used to examine the memory of
Nestin-GAC mice. (D) Protein lysates were prepared from whole brains and the
expression levels of GAC were determined by Western blot. (E) Densitometric
quantifications of the protein Levels were normalized to β-actin and presented as
fold change relative to that in wild-type whole brain lysates. (F) Tissue glutamate
levels were determined using the Amplex Red Glutamic acid/Glutamate Oxidase
Assay Kit. (G) Protein lysates from different regions of mice brain were prepared
and the expression levels of GAC were determined by Western blot.
Quantification data were normalized to β-actin and presented as fold change in
WT mice. Data are shown as the means ± SD. * and ** denote p < 0.05 and 0.01
compared with WT mice, N = 4 for Nestin-GAC and WT mice.
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Figure 3.8
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Figure 3.8. Brain-specific GLS1 overexpression increases EVs release in
vivo.
(A) Wild-type and Nestin-GAC mice were sacrificed at 12-16 weeks old. Brains
were removed, and for each brain, the right hemibrain was processed for EVs
isolation and the left hemibrain was homogenized for brain lysates. Protein
lysates were prepared from the EVs pellets in wild type and Nestin-GAC
hemibrains. The levels of EVs markers, tTG and flotillin-2 in the EVs lysates were
analyzed by Western blot. EVs protein loading was normalized with the weight of
their corresponding hemibrains before the EVs isolation. (B, C) Densitometric
quantifications of the protein Levels were presented as fold changes relative to
that in wild-type EV lysate. (D-F) Brain tissues from adult Thy1-GAC mice were
dissected and EVs were isolated using the same techniques described above.
EVs collected from WT (D) and Thy1-GAC (E) were evaluated via negative
staining under TEM. Images shown were representative of each group. EVs
numbers per vision fields (N = 10) were quantified. *** denotes p < 0.001
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Chapter 4
Potential mechanism of GLS1 in the regulation of extracellular vesicles in
macrophages and microglia
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4.1 Abstract
Extracellular

vesicles

(EVs)

are

important

in

the

intercellular

communication in the central nervous system and their release is increased upon
neuroinflammation and neurological disorders. Our previous data demonstrated
an increased release of EVs from HIV-1-infected macrophages and immuneactivated microglia that is neurotoxic. It also showed this release can be blocked
by the inhibition of ceramide production. However, the mechanism of increasing
EV release during HIV-1-infected and immune activation remains unknown. In
the current study, we investigated glutaminase 1 (GLS1), a mitochondrial
enzyme critical for glutamine metabolism, in EV release in HIV-1-infected
macrophages and immune-activated microglia. We propose that HIV-1 infection
increases GLS1, leading to a metabolic status that favors EV generation and
releases through the glutamine and lipid metabolism. This new understanding of
metabolic control of EV release in HIV-1-infected macrophages and immuneactivated microglia will shed light on HIV-1 pathobiology and neurological
complications.
Human primary monocyte-derived macrophages and murine microglia
BV2 cell culture system and macrophage-tropic HIV-1ADA and lipopolysaccharide
(LPS) were used to study the regulation of EVs during HIV-1 infection and
immune activation. EVs were isolated through differential centrifugations. GLS1
inhibitors, BPTES, and CB839 were used to specifically inhibit GLS1 activity.
Ceramide and alpha-ketoglutarate were added after the treatment of GLS1
inhibitors to study the change of EV release. Transmission electron microscopy,
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Nano-particle tracking analysis and Western blot were used to quantify the EVs
released from cells. Glutamate and glutamine levels were determined by reverse
phase high-performance liquid chromatography.
An elevated number of EVs was found in the supernatants of HIV-1infected macrophages and immune-activated microglia when compared with
controls. Conversely, blocking the GLS1 activity by BPTES, CB839 and CBX
significantly reduced EV release and glutamate generation in HIV-1-infected
macrophages and immune-activated microglia, suggesting a critical role of GLS1
in EV release. Consistently, the addition of glutamine substrate increases EV
release during HIV-1 infection or immune activation. Interestingly, the inhibited
EV release was reversed by the addition of ceramide and alpha-ketoglutarate.
Identifying these two factors as critical downstream effectors for GLS1 inhibitors.
In conclusion, these findings support GLS1 as an essential enzyme that
regulates through key metabolic intermediate ceramide and α-ketoglutarate
during HIV-1-infection and immune activation. Therefore, blocking EV release
through GLS1 inhibitors may serve as a novel therapeutic strategy to block the
adverse effect of EVs during HIV-1 pathobiology and neurological complications.
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4.2 Introduction
EVs have drawn attention by their facilitation of the interactions between
neurons and glial cells via their transfer of cargos. EVs are also been significantly
altered in response to stress and inflammation. EVs have been reported to be
associated with neurodegenerative diseases such as Alzheimer’s disease,
Parkinson disease, amyotrophic lateral sclerosis, prion disease and HIV-1associated neurocognitive disorders (HAND). The detection of EVs in various
biological fluids such as plasma and cerebral spinal fluid (CSF) provides a
potential role for EVs as biomarkers of diseases, including neurological disorders
[171, 179, 197-200]. EVs have been detected at an elevated level in the cerebral
spinal fluid in patients with mild to severe AD [167]. More importantly, protein
markers of EVs are present in neuritic plaques in AD brains [167, 201, 202]. Our
study also provided evidence of the increasing release of EVs in HAND models
[178]. However, the regulation of EVs formation and release needs to be further
elucidated.
GLS1 is a metabolic enzyme that is known to be associated with cancer
cell proliferation and transformation [173, 174]. GLS1 is also essential in the
glutaminolysis pathway, where it provides an energy source to the proliferating
cells and acts as a nitrogen substrate for lipid and protein synthesis [203-205].
During glutaminolysis, glutamine is catalyzed into glutamate and its subsequently
intermediate, α-ketoglutarate, which then enters the TCA cycle [110, 206, 207].
Glutamine serves as a nitrogen donor to protein glycosylation via the
hexosamine pathway [208, 209], and as a source for the production of
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glutathione in the resistance pathway against oxidative stress [205]. Furthermore,
glutamine metabolism has also been identified to be important in various CNS
diseases, including ALS, MS, and HAND [178, 210, 211]. Our recent reports
suggest that GLS1 is upregulated and responsible for the increasing release of
glutamate through elevated glutamine metabolism [72, 112]. More interestingly,
in our current study, we found that GLS1 is positively regulating the release EVs.
However, the mechanism of how GLS1 increases EV release remains unclear.
Furthermore, the role of glutamine metabolism in EV release remains
understudied.
Recent studies indicate that the formation and secretion of EVs are
largely dependent on the proper function of ceramide, which is a type of
sphingolipids

catalyzed

by

neutral

sphingomyelinase

(nSMase)

from

sphingomyelin. The defective metabolism of sphingolipids in the brain has also
been reported to be associated EVs with AD, where increasing EV release is
reported as a crucial contributor to the toxicity of amyloid beta and tau
phosphorylation [180]. The EV release is also reversed by the inhibition of the
nSMase pathway [212, 213]. Studies show that the nSMase inhibitor, GW4869
significantly reduces the release of EVs and its neurotoxicity in HIV-infected or
immune-activated macrophages and microglia and in AD model in vitro and in
vivo, indicating the potential involvement of ceramide in the EV biogenesis [178,
180, 214]. However, the correlation between GLS1, glutamine metabolism,
ceramide and EV hasn’t been investigated. Therefore, in this chapter, we will
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explore the possibilities and discuss the potential mechanism of GLS1 regulation
of EV release in response to the glutamine and sphingolipid metabolisms.
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4.3 Materials and Methods
Culture, HIV-1 and LPS infection of macrophages and microglia
Human peripheral blood-derived mononuclear cells were isolated through
leukopheresis from healthy donors. Human macrophages were differentiated in
Dulbecco’s Modified Eagle’s Media (DMEM) (Sigma Chemical Co., St. Louis, MO)
with 10% human serum, 50 µg/ml gentamycin, 10 µg/ml ciprofloxacin (Sigma),
and 1,000 U/ml recombinant human macrophage colony-stimulating factor
(MCSF) for 7 days. Human fetal microglial cells were obtained from fetal brain
tissue-derived microglia-astrocytes mixed cultures as previously described [185].
The HIV-1ADA strain was used to infect the macrophages and microglia at a
multiplicity of infection (MOI) of 0.1 and 0.5, respectively. After 24 hours, the
culture medium was changed to remove any remnant virus. Seven days after
HIV-1-infection, the culture medium was changed to glutamine-free neurobasal
medium for 24 h and supernatants were collected for subsequent HPLC or
Western blot analysis. HeLa and BV2 cell lines were obtained from ATCC, and
both cell lines were grown in DMEM with 10% fetal bovine serum and antibiotics.
Lipopolysaccharide (LPS) was used to immune activate BV2 cells for 24 h and
supernatants were collected for HPLC and Western blot analysis. Bis-2-(5phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) (a generous gift
presented by Dr. Tsukamoto from John Hopkins and later ordered from Millipore)
at a concentration of 10 µΜ was added to HIV-1-infected macrophages or LPStreated microglia prior to EV isolation. All experiments involving human cell
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samples are approved by Institutional Review Board of University of Nebraska
Medical Center.

Isolation of EVs from cells
EVs were isolated from the supernatants of GLS1-overexpressing cells,
HIV-1-infected macrophages and LPS-activated microglia through differential
centrifugations. Briefly, the supernatants were first centrifuged at 300 X g for 10
min to remove free cells, at 3,000 X g for 20 min to remove cellular debris and
then 10,000 X g for 30 min to remove free organelles. Lastly, EVs were collected
by ultracentrifugation at 100,000 X g for 2 h at 4°C. To prepare EVs for Western
blotting, the EV pellets were lysed in M-PER mammalian protein extraction
reagent (Thermo Scientific, Pittsburgh, PA). For negative staining, EVs were
fixed in 2% glutaraldehyde and 2% paraformaldehyde. For glutaminase activity
assay and neurotoxicity, the EVs were resuspended in 1 ml of glutamine-free
neurobasal medium.

Negative staining and electron microscopy
EVs were fixed and then spread on the silicon monoxide and nitro-cellular
film coated copper grid. The droplets were removed with filter paper, air-dried at
room temperature and then subjected to transmission electron microscopy (TEM).
For scanning electron microscope (SEM), cells were fixed in 2% glutaraldehyde
and 2% paraformaldehyde and point dried, mounted and coated with
gold/palladium.
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Nano-particle tracking analysis
A NanoSight NS 300 (Malvern) equipped with an sCMOS camera was utilized to
analyze the size distribution and concentration of EVs. NanoSight utlizes
Nanoparticle Tracking Analysis (NTA), which is a combination of light scattering
and Brownian motion technologyto measure the concentration and size

and

distribution of particles in the EV supernatants. After the whole process of EV
isolation, the pellets were first resuspended in 100 µl of filtered PBS and then
diluted by 100 times. The conditions of the measurements include temperature of
25 °C, viscosity of 1 cP, 25 seconds per capture frame and a measurement time
of 60 s. All of the conditions were kept the same amongst all of the samples. The
results indicate the mean sizes and concentration of at least three individual
measurements.

Toxicity/MTT/MTS assays
GLS1 inhibitors were added to HIV-1-infected macrophage or LPSactivated microglia cultures and cell viability was assessed by MTT assays in 24well or 96-well plates.

MTT (Sigma) was added to the cultures for a final

concentration of 125 µg/ml. The plates were incubated for 30 minutes at 37 °C
with 5% CO2 and the medium was aspirated. The insoluble formazan was
solubilized in DMSO, and the concentrations were determined by optical density
at 490 nm with an ELX808 densitometer (Bio-Tek Instruments, Winooski, and
VT). Alternatively, Celltiter aqueous one solution cell proliferation assay, which
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contains

a

novel

tetrazolium

compound

[3-(4,5-dimethylthiazol-2-yl)-5-(3-

carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) was
utilized to assess cell viability according to the manufacturer instructions. Briefly,
20 µl of reagent was added into a 100 µl of culture medium, and then the plates
were incubated the plates in a humidified, 5% CO2 and 37 °C atmosphere for 1
hour. The absorbance was determined at 490 nm.

Western blot
Protein concentrations were determined by Bradford protein assay. SDS
PAGE separated proteins from whole cell and EVs lysates. Afterwards they were
electrophoretically transferred to polyvinyldifluoridene membranes (Millipore,
Billerica, MA and Bio-Rad, Hercules, CA). Membranes were incubated overnight
at 4 °C with polyclonal antibodies for KGA and GAC (Dr.N.Curthoys, Colorado
State University, Fort Collins, CO), tissue transglutaminase (tTG) (Lab
Vision/Thermo, Fremont, CA), flotillin-2 (Cell Signaling Technology, Danvers, MA)
and β-actin (Sigma-Aldrich, St. Louis, MO), followed by horseradish peroxidaselinked secondary anti-rabbit or anti-mouse secondary antibodies (Cell signaling
Technology). Antigen-antibody complexes were visualized by Pierce ECL
Western Blotting Substrate. For quantification of the data, films were scanned
with a CanonScan 9950F scanner and images were analyzed using the public
domain NIH image program (developed at the U.S. National Institutes of Health
and available on the internet at http://rsb.info.nih.gov/nih-image/).
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Glutaminase activity assay
Highly concentrated whole cell lysates were collected from flasks and
subjected to GLS activity assay using a two-step assay [187, 188]. Briefly,
protein concentrations in the lysates were tested by using BCA Protein Assay Kit
(Pierce). All samples were normalized to same concentration. In the first step,
fifty milligrams of protein was added to 100 µL of initial assay mix. The mix
contains 50 mM glutamine, 0.15 M phosphate, 0.2 mM EDTA, and 50 mM trisacetate. The PH value of the mix was adjusted to 8.6 and incubated at 37 °C for
30 min. 10 µL of 3 N hydrochloric acid (HCl) was added to inactivate the
glutaminase activity and stop the reaction. In the second step, 1 mL of the
second reaction mix was added, which contained 0.4 mg of purified bovine liver
glutamate dehydrogenase (Sigma-Aldrich, St. Louis, MO, USA), 0.08 M Trisacetate at pH 9.4, 0.2 M hydrazine, 0.25 mM ADP (adenosine 5'-diphosphate
sodium salt), and 2 mM NAD (β-nicotinamide adenine dinucleotide hydrate). The
samples were mixed and incubated for 30 min at room temperature. 100 µL of
reaction was used for measurement and absorbance was determined at a
wavelength of 340 nm, glutamate concentration was determined using a
standard curve of 10, 5, 2.5, 1.25, 0.625, and 0.0 mM glutamate, along with
negative controls.

Analysis of glutamate and glutamine by RP-HPLC
Glutamate levels were analyzed by RP-HPLC using an Agilent 1200 liquid
chromatograph and fluorescence detector as previously described [14] with a few
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modifications. The experiments utilized 4.6 × 75 mm, 3.5 µm ZORBAX Eclipse
AAA analytical columns (Agilent). A gradient elution program was optimized for
glutamate measurement with a flow rate 0.75 ml/min.

Analyses of glutamate concentrations
The intracellular glutamate levels in whole brain lysates of mice and whole
cell lysates were determined by Amplex Red Glutamic acid/Glutamate Oxidase
Assay Kit (Invitrogen) based on the manufacturer’s instruction. Brain tissue
lysates and whole cell lysates were diluted to the same protein concentration
before the assay.

Statistical analysis
Data are expressed as means ± SD unless otherwise specified. Statistical
analysis was performed using ANOVA, followed by the Tukey-post-test for paired
observations. Significance was determined by a p value < 0.05. All experiments
were performed with cells from at least three donors to account for any donorspecific differences. Assays were performed at least three times in triplicate or
quadruplicate within each assay.
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4.4 Results
EV release in HIV-1-infected macrophages is dependent on glutamine.
Our previous work has demonstrated the role of GLS1 in the regulation of
EV release. However, the mechanism of how GLS1 regulates the release
remains unclear. To further study our hypothesis, different concentrations of
glutamine were added to HIV-1-infected macrophages one day prior to harvest
when media was changed into serum free DMEM. Three different concentrations
were used, including 1 mM, 2 mM and 5 mM. EVs were isolated from the
supernatants collected from HIV-1-infected macrophages and subjected to
negative staining. TEM was used to capture images of EVs at magnification of
2700 X (Fig 4.1A-D) and 42,000 X (Fig 4.1E-H). Seven random fields were
chosen by the instructor at the TEM core facility lab, who is blinded from the
experiments and samples identifications. Quantification of EVs showed a
significant increase of EVs at a concentration of 1 mM and high concentrations of
glutamine-treated groups remain a high EV release but no significant dosedependent effect (Fig 4.1A-I). The extracellular supernatants were then prepared
for RP-HPLC. Glutamate generation was found to be increased with the
increasing concentrations of glutamine in the supernatants (Fig 4.2A, B). We
collected protein lysates from both the whole cells and EVs. The expression level
of GAC under different concentrations of glutamine did not change compared to
control group. GAC was also detected in the EVs as previously reported [178].
EV markers, Alix, flotillin-2 and CD9 were also detected using Western blot. The
level of EV markers in the whole cell level is consistent. However, EV markers
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were higher in HIV-1-infected macrophages with glutamine concentrations of 1
mM and 2 mM. Surprisingly, the 5 mM treatment group did not show a significant
increase of EV markers as compared with the control. These results indicate that
the presence of glutamine is important for the EV release in HIV-1-infected
macrophages.

EV release in immune-activated microglia is dependent on glutamine.
To further investigate whether EV release is dependent on glutamine, BV2
cells were utilized to study the association of glutamine and the regulation of EV
release. Different concentrations of glutamine were added six hours prior to LPS
treatment. The presence of glutamine boosted the survival of BV2 cells,
indicating the importance of glutamine (Fig 4.3A). The extracellular glutamate is
increased significantly at the increasing level of glutamine added to the cell
cultures. Nanoparticle tracking analysis showed that EV release was increased at
the concentration of 2 mM or 5 mM (Fig 4.3B, C). Furthermore, the Western blot
of whole cells showed increased GAC levels at 2 mM and 5 mM glutamine
concentrations (Fig 4.3E, F). The Western blot of EVs showed an increase in the
EV markers, Alix and flotillin-2, at increased glutamine concentrations (Fig 4.3E,
G, H). Altogether, these results demonstrated that glutamine is involved in the EV
release in immune-activated microglia cells.

EV release in immune-activated microglia is associated with the level of αketoglutarate.
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Glutamine metabolism is an essential process to generate glutamate and
thus α−ketoglutarate for energy production. To further study the potential
pathway of GLS1-associated EV release, 1 mM of α−ketoglutarate (α−KG) was
added with GLS1 inhibitors. Cell viability did not change upon treatment of GLS1
inhibitors and α−KG (Fig 4.4A). Whole cells lysates were collected and subjected
to a GLS1 enzyme activity assay. GLS1 activity increased after LPS treatment
and decreased after the treatment of GLS1 inhibitors in the presence of 1 mM
α−KG (Fig 4.4C). EVs were then either isolated and resuspended using filtered
PBS or lysed for Western blot. EVs were diluted for 100 times and subjected to
nanoparticle tracking analysis. The decreased EV release after GLS1 inhibitors
treatment was significantly reversed by the addition of α−KG (Fig 4.4B).
Furthermore, EV lysates were subjected to Western blot. With the presence of
α−KG, the level of EV markers, Alix and flotillin-2 were significantly increased
even with the treatment of GLS1 inhibitors, BPTES or CB839 (Fig 4.4D-F). These
results suggest that α−KG could be the downstream product of glutamate that is
associated with the regulation of EV release.

EV release in immune-activated microglia is associated with sphingolipid
metabolism.
Our previous report has shown that the release of EV can be blocked by
the presence of the nSMase inhibitor, GW4869, which is an inhibitor of the
production of ceramide [178]. Therefore, we hypothesized that adding ceramide
to the LPS-treated BV2 with GLS1 inhibitors would help restore the release of
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EVs. To test this hypothesis, we used two concentrations of ceramide, 50 µM or
100 µM with or without GLS1 inhibitors. LPS-treatment and GLS1 inhibitors
treatment with or without ceramide didn’t induce cell loss (Fig 4.5A). 50 µM of
ceramide was utilized for following experiments. GLS1 activity increased after
LPS treatment and decreased after the treatment of GLS1 inhibitors in the
presence of ceramide (Fig 4.5B). Nanoparticle tracking analysis results showed
that when 10 µM BPTES or CB839 was added, the release of EVs was
decreased. Interestingly, when ceramide was added, the release of EVs
increased (Fig 4.5C), indicating that the ceramide pathway of sphingolipid
metabolism is involved in GLS1 regulated release of EVs.
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4.5 Discussion
Our current study has focused on the identification of key pathogenic
components for HAND. Our previous studies demonstrated a strong link between
GLS and the pathogenesis of HAND via the overproduction of glutamate and
related neuronal damage [49, 53, 71, 72, 108, 188]. Over the years, GLS1 has
garnered more attention regarding the essential role it plays in normal and
pathological human physiology. The knockout of GLS1 leads to lethal offspring
one day after birth in mouse models, which indicates the critical role of GLS1 in
the early development. We have also reported that GLS1 is essential for the
proper functioning of neural progenitor cells including neuronal survival together
with proliferation and differentiation [215]. During neuroinflammation, the
activation of GLS1 and subsequently upregulated levels of GLS1 are associated
with HIV-1 infection or immune activation and subsequent neurotoxicity [178].
In previous reports, it has been reported that GLS1 is involved in the
regulation of EV release. However, the exact mechanism remains to be
elucidated. In this study, we presented three major findings regarding the
potential mechanism of EV release. First, the release of EVs is dependent on the
presence of glutamine and its product glutamate. Second, the downstream
product of glutamate, α−KG, can reverse the inhibition of EV release by GLS1
inhibitors, indicating that α−KG could be an effector for EV release. Third, the
inhibition of EV release via GLS1 inhibitors could be mediated by the
sphingolipid, ceramide pathway, as we have shown the addition of ceramide can
rescue the reduced EV release. These observations suggest that GLS1 could
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regulate EV release through the glutamine metabolism and sphingolipid
metabolism.
To investigate our hypotheses on the mechanisms of GLS1’s regulation of
EV release, we tested the concentrations of isolated EVs from groups including
glutamine-deprived, or 1 mM, 2 mM and 5 mM of glutamine. A wider range of
glutamine concentration was utilized in order to study the effects of lower levels
of glutamine on EV release. When 0.04 mM or 0.2 mM of glutamine was used to
treat LPS-stimulated BV2 cells, the EV concentrations didn’t show a significant
increase compared with the control group. Changes in EV release were only
observed till at a lowest glutamine level of 1 mM. The average sizes of the
isolated EVs were consistent in all treatment groups, which were above 100 nm
(data not shown). LPS treatment also did not alter the size of the released EVs.
However, the increase of glutamine concentration from 1 mM to 5 mM did not
show a significant or dose-dependent trend of increase of EV release, indicating
the necessity of glutamine in the culture to release EVs. A potential rationale is
that glutamine metabolism provides a possible energy resource for the EV
budding. However, the detailed mechanism needs to be further elucidated.
When glutamine is involved in the EV release, the downstream product, αKG, which is dependent on glutamine, could be an important regulator for EV
release. Therefore, after the addition of GLS1 inhibitors, BPTES or CB839, to
LPS-treated BV2 cells, 1 mM of α-KG was also added to the cultures prior to EV
isolation. Interestingly, the presence of α-KG rescued the reduced EV release
after treatment with GLS1 inhibitors. The inhibition of glutamate production from
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GLS1 inhibitors leads to a reduced generation of α-KG. When α-KG was
compensated, the level of EV release was rebooted, indicating that the EV
release could be regulated through glutamine and α-KG. However, further study
is warranted on whether the addition of α-KG boosts production of glutamate, or
if this effect is due to the direct actions of α-KG. One possibility is that when αKG enters the TCA cycle, energy production is increased. The increase
production of ATP could activate the increased release of EV via P2X7 receptors,
which could also be a further action of the mechanism.
Previously, we reported using GW4869 could effectively inhibit the release
of EVs in HIV-1-infected macrophages and LPS-treated microglia [178]. Studies
have also shown that GW4869 could inhibit EV release in vitro and in vivo in AD
models and prion diseases [180, 214, 216-220]. It has also been reported that
sphingolipid metabolism could be involved in EV release in microglia and
neurological diseases [213, 221]. However, the role of sphingolipid metabolism in
GLS1-associated EV release has never been reported. Therefore, ceramide was
added to LPS-treated BV2 cells with GLS1 inhibitors. The NanoSight results
demonstrated a rescue of EV release of ceramide to GLS1 inhibitors, which
indicates ceramide could be involved in the pathway of GLS1-regulated EV
release. The connection of ceramide pathway with glutamine metabolism has
barely been investigated. Research has suggested a potential role of glutamine
and glutamate in the essential supply of nitrogen bond to lipid biosynthesis
including sphingolipids. Whether ceramide could be the downstream or upstream
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product of this pathway remains unclear. The association between of ceramide
and α-KG or energy production is also understudied.
Further investigation is needed for the relation between sphingolipids and
GLS1 levels. After the treatment of GLS1 inhibitors, the activities and expression
level of neutral sphingomyelinases needs to be measured. The level of ceramide
would be assessed through mass spectrometry, which will provide further
evidence for the association between ceramide, glutamine, and GLS1 in EV
release.

The

other

components

in

the

sphingolipids

family,

including

sphingomyelin, sphingosine and etc. should also be assessed to uncover the
potential pathways to link these effectors to EV release. Furthermore, cholesterol
has been reported to be associated with EV release [222, 223]. However, the
involvement of cholesterol in GLS1-regulated EV release is unknown. These
further investigations can shed light on the detail mechanisms of how GLS1
regulates EV.
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4.6 Conclusion
In summary, the regulation of GLS1 in EV release is associated with
glutamate, and its downstream product, α−KG and the sphingolipid, ceramide,
which implicates the importance of glutamine metabolism and sphingolipid
metabolism in EV release. This new mechanism will shed insight on the
regulation of EVs and provide potential therapeutic targets for HAND and some
types of neoplasms.
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4.7 Tables and Figures
Figure 4.1
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Figure 4.1. EV release in HIV-1-infected macrophages is dependent on
glutamine.
(A-H) MDM was infected by HIV-1 virus for 6 days, and the medium was
changed into serum free glutamine-free DMEM. Additional glutamine was added
to the medium at the concentrations of 1 mM, 2 mM and 5 mM. EVs were
isolated

through

differential

centrifugation

and

resuspended

upon

the

concentrations of whole cell lysates. EVs were fixed and subjected to negative
staining using TEM under a magnification of 2700 X (A-D) and 42,000 X (E-H). (I)
EVs numbers in E to H were quantified by manually counting from a total of 7
random vision fields. Results are representative of TEM images and
quantification results are means ± SD of EV numbers from 7 fields of TEM
images. *** denotes p < 0.001 in comparison to controls.
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Figure 4.2
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Figure 4.2. EV release in HIV-1-infected macrophages is dependent on
glutamine.
MDM was infected by HIV-1 virus for 6 days, and the medium was changed into
serum free glutamine-free DMEM. Additional glutamine was added to the
medium at the concentrations of 1 mM, 2 mM and 5 mM. (A, B) Supernatants
were collected and centrifuged at 1,500 rpm for 5 min to remove cells. Samples
were prepared for RP-HPLC and the levels of glutamate and glutamine were
determined. (C) Protein lysates were prepared from whole cell lysates and EVs
pellets. The levels of GAC and EVs markers Alix, flotillin-2 and CD9 were
analyzed by Western blot. EV protein loading was normalized with protein
concentrations in whole cell lysates. (D) Densitometric quantification of the
protein level of GAC in whole cell lysates was presented as fold change relative
to β−actin. (E-G) Densitometric quantifications of the protein levels of EV markers
were presented as fold changes relative to that in mock-infected control EV
lysates. Western blot results shown are representative of three independent
experiments. Quantification results shown are means ± SD of experiments
performed in triplicate (n = 3 donors). *, ** and *** denotes p < 0.05, 0.01 and
0.001, compared with that of the control microglia cells.
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Figure 4.3
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Figure 4.3. EV release in immune-activated microglia is dependent on
glutamine.
When BV2 medium was changed into serum free glutamine-free DMEM,
additional glutamine was added to the medium at concentrations of 1 mM, 2 mM
and 5 mM 6 hours prior to LPS treatment. (A) Cell viability was measured after
overnight treatment using MTS assay. (B, C) Supernatants were collected and
centrifuged at 1,500 rpm for 5 min to remove cells. Samples were prepared for
RP-HPLC and the levels of glutamate and glutamine were determined. (D)
Quantifications of NanoSight NTA of vesicle concentration for samples from LPStreated BV2 cell with different glutamine concentrations. (E) Protein lysates were
prepared from the whole cell lysates and EVs pellets. The levels of GAC and EVs
markers, Alix, flotillin-2 and CD9 were analyzed by Western blot. EVs protein
loading was normalized with protein concentrations in whole cell lysates. (F)
Densitometric quantification of the protein level of GAC in whole cell lysates was
presented as fold changes relative to β−actin.

(G,

H)

Densitometric

quantifications of the protein levels in EV markers were presented as fold
changes relative to that in mock-infected control EV lysates. Western blot results
shown are representative of three independent experiments. Quantification
results shown are means ± SD of experiments performed in triplicate (n = 3
donors). *, ** and *** denotes p < 0.05, 0.01 and 0.001, compared with that of
control microglia cells.

135
Figure 4.4
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Figure 4.4. EV release in immune-activated microglia is associated with the
level of α-ketoglutarate.
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM
medium when GLS1 inhibitors were added. Two hours prior to LPS treatment, 1
mM of α-ketoglutarate was added to BV2 cells. (A) Cell viability was measured
after overnight treatment using MTS assay. (B) After 1 mM of α-ketoglutarate
treatment, Nanoparticle tracking analysis was conduct with 100 X dilution of
collected EVs with filtered PBS. Quantifications of the NanoSight NTA of vesicle
concentration for samples from LPS-treated BV2 cell with GLS1 inhibitors and αketoglutarate. (C) Protein lysates were collected from LPS-treated BV2 cells with
or without GLS1 inhibitors or α-ketoglutarate. GLS1 activities were determined by
the enzyme activity assay. (D) Protein lysates were prepared from EV pellets.
The levels of GAC and EVs markers, Alix and flotillin-2 were analyzed by
Western blot. EVs protein loading was normalized with protein concentrations in
whole cell lysates. (E, F) Densitometric quantifications of the protein levels of in
EV markers were presented as fold change relative to that in mock-infected
control EV lysates. Western blot results shown are representative of three
independent experiments. Quantification results shown are means ± SD of
experiments performed in triplicate (n = 3 donors). *, ** and *** denotes p < 0.05,
0.01 and 0.001, compared with that of the control. #, and ### denotes p < 0.05 and
0.001 compared with that of the LPS-treated group.
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Figure 4.5
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Figure 4.5. EV release in immune-activated microglia is associated with
sphingolipid metabolism.
BV2 cells were treated with 10 µM BPTES or 10 µM CB839 4 hours prior to LPS
treatment overnight. BV2 cell regular medium was changed to serum-free DMEM
medium when GLS1 inhibitors were added. Two hours prior to LPS treatment, 50
µM or 100 µM ceramide was added to BV2 cells. (A) Cell viability was measured
after overnight treatment using MTS assay. (B) Protein lysates were collected
from LPS-treated BV2 cells with or without GLS1 inhibitors or ceramide. GLS1
activities were determined by the enzyme activity assay. (C) After 50 µM
ceramide treatment, Nanoparticle tracking analysis was conduct with 100 X
dilution of collected EVs with filtered PBS. Quantifications of the NanoSight NTA
of vesicle concentration for samples from LPS-treated BV2 cell with GLS1
inhibitors and ceramide. * and *** denotes p < 0.05 and 0.001, compared with
that of the control.
group.

###

denotes p < 0.001 compared with that of the LPS-treated
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Chapter 5
General summary and future directions
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5.1 Summary and General Discussion
Chronic neuroinflammation has been a hallmark of HAND, despite
advances in HARRT. As such, a certain extent of cognitive impairment still exists
and greatly affects patient quality of life. As the HIV-1 virus does not directly
infect neurons, neuronal injury and synaptic damage are attributed to the HIV-1infected macrophages and microglia, which are believed to be the reservoir of
HIV-1 [42, 224, 225]. Among HIV-1-infected macrophages and microglia, the
production and release of the soluble neurotoxic factor, glutamate, is known to
contribute to the induction of extensive neuronal injury and brain inflammation [46,
50, 72, 74, 226, 227].
Over last decade, our lab has focused on the study of GLS1 in HAND.
Significant evidence indicates that during HIV-1 infection GLS1 is upregulated
and translocated from the inner membrane of mitochondria to cytosol [149].
GLS1 has also been detected in extracellular supernatants [188]. However, it
was unknown how GLS1 is released from cytosol to extracellular space.
Therefore, as discussed in chapter two, we investigated the role of EVs in
carrying GLS1 as a cargo and as a facilitator of GLS1 release. We have shown
that GLS1-containing EVs are able to acquire the GLS1 activity and generate
more glutamate in the extracellular space or ex vivo. Using RP-HPLC to detect
the level of glutamate in incubated EV supernatants, the production of glutamate
was reversed by the addition of GLS1 inhibitors, which suggests GLS1 in EVs
contributes to the generation of the excess levels of glutamate. The location of
GLS1 in EVs remains undetermined. However, the detection of vGLUT1 in EVs
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from macrophages and microglia suggests that during the budding of EVs from
the plasma membrane, a transporter for glutamate is also translocated on the
EVs. This facilitates the possible GLS1 activity in the EVs. The other contents in
the EVs isolated from HIV-1-infected macrophages or immune-activated
microglia have not been reported in the database for EVs, or exosomes online,
which indicates the urgent need for detailed analysis of EV contents.
Interestingly, during the investigation of GLS1 release, we found that the
presence of GLS1 inhibitors in the whole cell cultures not only affects the
intracellular and extracellular glutamate level but also affect the level of EV
secretion. A recent study reported that the production of EVs and their cargo
could be interactively associated and regulated in retinal epithelial cells [228].
Therefore, we decided to investigate whether the EV cargo, GLS1 can also be
involved in the regulation of EV release. An adenovirus construct was generated
to overexpress both GLS1 isoforms, KGA and GAC in cells. The overexpression
of GLS1 significantly increases the GLS1 activity and glutamate generation
intracellularly and extracellularly. More importantly, the secretion of EVs was
increased upon overexpression of GLS1, indicating the potential regulation of
GLS1 in EV release. To further prove our hypothesis, we tested GLS1 inhibitors,
BPTES, CB839, L-DON and CBX, a newly discovered blocker in HeLa cells, HIV1-infected macrophages and immune-activated murine and human microglia.
The inhibition of GLS1 significantly attenuates the release of EVs in all these
types of cells, where GLS1 also is released in EV as cargos. This regulation
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prompted us to further study what can be the potential mechanism of GLS1
regulating EV secretion.
The most direct link is the production of GLS, glutamate, which is affected
instantly by the addition of GLS1 inhibitors. When different concentrations of
glutamate were added, we did not observe a dose-dependent EV release.
However, when glutamine was deprived, the EV level was significantly reduced,
indicating the essential role of glutamine in the secretion of EVs. Glutamate is
also known as a substrate that will be converted into α-ketoglutarate, which is a
key intermediate of TCA cycle and Krebs cycle. Therefore, we added α-KG to
LPS-treated BV2 cells with or without GLS1 inhibitors. The results showed that
the α-KG along to control or LPS treated BV2 cells did not increase the level of
EV release, where glutamine was present and glutamate production was not
suppressed. However, when GLS1 inhibitors were added to LPS-stimulated BV2
cells, the GLS1 activity was significantly reduced and the release of EV was
significantly decreased. When α-KG was added to the culture, the GLS1 activity
was still reduced, indicating α-KG did not interrupt the function of GLS1 inhibitors.
However, the release of EV was rescued from the inhibition of GLS1 blockers,
which suggests α-KG as a downstream effector for the regulation of EVs. Further
investigation is still needed to test the level of extracellular glutamate and
intracellular glutamate level to determine whether α-KG rescues the EV release
by reverse reproducing glutamate or a direct effector on further downstream
pathways. Since both glutamine metabolism and α-KG have been know as

143
important energy sources, the role of energy production could be linked in this
mechanism.
Previously, we have proven that the inhibition of ceramide production can
prohibit the secretion of EVs to the extracellular space and thus rescue the
GLS1-associated glutamate-induced neurotoxicity. Ceramide has been believed
to be involved the formation of multivesicular bodies [134]. EVs have been
reported to be secreted in a ceramide-dependent pathway. However, the
association between GLS1-regulated EV release and ceramide has not been
investigated. Therefore, 50 µM of ceramide was added to GLS1-inhibitors treated
BV2 cells after LPS stimulation. The ceramide tended to rescue the reduced EV
release after GLS1 inhibition. However, the effect is not as significant as α-KG.
One possibility is that α-KG could be more direct downstream of EV release.
More important questions are what the association between α-KG and ceramide
is unclear and what the link between the glutamine metabolism and sphingolipid
metabolism remains to be elucidated.
With the evidence of the important role of GLS1 in the regulation of EV
secretion in vitro, we also testify its regulation in vivo. Over last 5 years, we have
developed, generated and characterized a GLS1-overexpressing mice model to
better study HAND pathogenesis. These Nestin-GAC mice showed a significant
increase of GAC and intracellular glutamate specifically in brain areas, including
the hippocampus, cortex, midbrain and cerebellum but not in kidney. The NestinGAC mice exhibited significant cognitive impairment in learning and memory.
Increasing apoptosis and gliosis were also found in this model correlated with the
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increasing amount of glutamate. More importantly, EV release in the brain was
detected increased. This observation gives us a great inspiration that by
inhibiting EV release and GLS1 release through GLS1 inhibitors, we can study
the potential rescue effect from glutamate-associated neuronal injury. This in vivo
study can truly provide an insight of the pathogenesis of HAND and further a
therapeutic target and potential treatment for HAND.
Taken together, these results demonstrate a better understanding of the
pathogenic role of GLS1 and EV in HIV-1-infected macrophages and microgliarelated to HAND (Fig 5.1). The importance of glutamate-associated neurotoxicity
and neuronal injury has merged to be an important target for HAND patients. EVs
are no longer considered as a biomarker or degrading mechanism for unwanted
cellular compartments but present as a critical pathogenic component during
neuroinflammation and immune activation. The understanding of the mechanism
of EV release, GLS1, glutamine metabolism and sphingolipid metabolism
definitely sheds light on to a potential pathway not only in neuroscience but also
in cancer research and other broader aspects.
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5.2 Future directions
5.2.1

The

role

of

EVs

in

macrophage/microglia-specific

GLS1-

overexpressing mice
For this study, we focused on the regulation of EV release in
macrophages and microglia in vitro. When studying this phenomenon in vivo, due
to the limitation of our mouse model, we utilized the Nestin-GAC and Thy1-GAC
mouse to assess the effect of GLS1 on EV release. These two models majorly
overexpress GLS1 in most of the regions of the brain. However, to further
investigate the regulation of EV release in macrophages and microglia, we are in
the process of generating the macrophage-specific and microglia-specific GACoverexpressing mice to better study the specific role of GLS1 in the release of
EVs in vivo. We will compare the behavioral impairment of the macrophagespecific and microglia-specific GAC-overexpressing mice with that of the NestinGAC mouse model. We will also examine the expression of GLS1 and
intracellular glutamate levels in different regions of the mouse brain.
Furthermore, the level of EV release will be assessed and compared using TEM,
nanoparticle analysis and Western blot. GW4869, an inhibitor of neutral
sphingomyelinase and EV release will be injected intraperitoneally into the mice
immediately after the induction of GLS1 overexpression to evaluate the change
in neuroinflammation and EV release in the brain. Furthermore, the GLS1
inhibitors, including CBX, BPTES and CB839, will also be injected to further
assess the role in the regulation of EV release. The levels of sphingolipids in the
brain from different treatments will also be determined and compared using mass
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spectrometry. These future experiments will further expand our knowledge of
GLS1 regulating EV release in vivo.

5.2.2 The role of EVs in GLS1 cKO mice
The previous generation of GLS1 KO mice was not successful due to the
lethal developmental deficiencies in the respiratory system. This has caused
additional challenge for further investigations into GLS1 functions and its
mechanisms. Therefore, we are in the process of generating GLS1 conditional
KO mice by crossing the GLS1-floxed mice with Csf1R-CreER mice. In this new
Csf1R-GLS1-/- mouse model, GLS1 will be knocked out specifically from
macrophages and microglia with temporal control of tamoxifen. The level of EV
release from the mice brain will be assessed. Furthermore, we will cross the
Csf1R-GLS1-/- mouse with HIV-Tat transgenic mice to investigate the effects of
deletion of GLS1 in macrophages and microglia. Specifically we will be looking at
reversing the destructive effects of the HIV-Tat mouse by assessing the
behavioral parameters, brain inflammation levels, and electrophysiological
functions. The release of EVs will also be examined to further confirm the role of
GLS1 in the regulation of EV release. If our hypothesis is proven to be true, the
newly developed GLS1 inhibitors from our lab could be a novel therapeutic
method for HAND patients.

5.2.3 The role of extracellular vesicles in astrocytes
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In the general microenvironment of the brain, astrocytes are abundant and
play a crucial role during inflammation and neurodegenerative disease. In HAND,
reports show that astrocytes contribute to CNS damage through the toxic and
pro-apoptotic signaling to neighboring cells. During HIV infection, the glutamate
metabolism and transportation is impaired in astrocytes, which further leads to
access extracellular levels of glutamate. Additionally, astrocytes release EVs that
contains ATP, lipid droplets, and miRNA that induces neurotoxicity. Our
preliminary data has shown that the treatment of TNF-α and IL-1β on astrocytes
alters the level of GLS1 and consequently the release of EVs. Interestingly, the
GLS1 inhibitors, BPTES and CBX reversed the elevated EV release, which
further indicating the regulation of EV release via GLS1.

5.2.4 The role of extracellular vesicles in stem cell biology
GLS1 has also gained significant attention in cancer research as a
therapeutic target [204, 229, 230]. Aberrant glutamine metabolism has been
found in many neoplastic cells, and has been noted to promote the proliferation,
transformation, invasion and metastasis of said neoplastic cells [174, 231-234].
Interestingly, EVs released from neoplasms have been reported to modify the
cancer stem cells (CSCs) niche via the promotion of angiogenesis, tumor cell
proliferation and metastasis [235-239]. EVs isolated from body fluids of cancer
patients, including blood, ascites fluid, urine, and CSF, can modulate the
metastatic niche through various growth factors and cytokines. EVs have also
been utilized in the study of neurogenesis and stem cell therapy. However, the
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direct role of EVs in the neurogenic niches has not yet been addressed. Potential
roles include cellular and molecular mechanisms of exosomal regulation
A casual relationship between neurogenesis and neurodegenerative
diseases has been revealed. In this case, the strong association of EVs and
various neurodegenerative disorders, such as AD, PD, Prion disease and HAND
provides the evidence that EVs may also play an important role in the neurogenic
role in the brain microenvironment as powerful regulators, biomarkers, and
therapeutic targets. Furthermore, our lab has reported that GLS1 is essential for
the differentiation, survival and proliferation of human neural progenitor cells.
This indicates the potential correlation between EVs, GLS1 and neural stem cell
biology, which would be a novel future project.
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5.3 Tables and Figures
Figure 5.1

Figure 5.1 Scheme of EV release associated with GLS1, glutamine and
sphingolipid metabolism.
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